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ABSTRACT
The central function of the vascular system is the transportation and distribution of
blood throughout the body. Occurrence of various forms of vascular disease, in which this
central function is compromised, is associated with high mortality and morbidity rates.
Vascular disease is an active and multifactorial process causing changes in local
hemodynamics and blood vessel wall mechanics. The work presented here aims to advance
the current knowledge on the role of local geometrical parameters in vascular disease and
endovascular intervention modalities. In our first set of studies, we develop a
computational framework to understand the role of aortic geometry in abdominal aortic
aneurysm wall mechanics, with the purpose of predicting peak wall stress and the risk of
rupture. In our next set of studies, we seek to understand possible associations between
local hemodynamics and geometric variables in severe carotid artery stenosis (CAS). Using
key geometric descriptors of CAS, we formulate stress-based prediction models that can
be useful in disease progression risk stratification. In regard to geometric analyses in an
endovascular device technology, studies are focused on identifying microstructurefunction relations in drug-coated balloon (DCB) therapy and developing upon current DCB
excipient design. The DCB therapy is an emerging intervention procedure with a great
scope for improvement, that integrates angioplasty with local drug delivery to restore
lumen patency at atherosclerotic lesion sites. Taken together, results from these studies can

contribute to clinical practices and healthcare market in capacities including disease
severity diagnosis, surgical decision making, and endovascular therapy technologies.
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CHAPTER 1
INTRODUCTION
1.1

CLINICAL MOTIVATION
Despite advances in diagnostic and therapeutic interventions aimed at eradication

of vascular disease, it remains the leading cause of morbidity and mortality in the United
States. Vascular disease is often referred to as pathological state of arteries, includes
coronary artery diseases and peripheral artery disease (PAD) as well as stroke and
aneurysms. Most vascular disease affect older adults; In the United States 16.5 million
individuals are affected by coronary artery disease, 8-12 million people various types of
PAD and almost a million people have a stroke every year

1,2

. The incidence of various

types of vascular disease creates $400 billion burden annually, which is estimated to be
increasing 3.
Vascular Disease
Vascular disease can be diverse in terms of mechanism and pathophysiology, yet
various phenotypes of vascular disease can be identified with some abnormalities in
geometric characteristics. These geometric alterations are believed to reflect the
development of vascular disease and exacerbate function and pathology progression.
Medical diagnosis of the disease and determining the severity of pathology is closely
associated with the following intensity of treatment that directly affects clinical outcome 4.

1

The systematic consideration of vascular geometry in relation to a pathological state can
determine healthcare actions and outcome in a worthwhile manner. Thus, there is a
substantial need to utilize more selective approaches in clinical decision making to
intervene or manage disease progression, as perioperative and long-term risks of vascular
repair procedures still figure prominently 5–7. Below, two cases are discussed in detail.
Abdominal Aortic Aneurysm
Abdominal aortic aneurysm (AAA) is closely associated with rupture-related death
and procedural risks

8–10

. AAA development is unequivocally a multifunctional process

involving systematic changes in material composition and mechanical behavior, and
followed by focal geometric adaptations. A mechanism postulated for AAA formation
focuses on inflammatory processes that lead to matrix metalloproteinases production and
elastase release; a chain of events thought to be associated with enzymatic degradation of
structural proteins and AAA expansion 11,12. Further regional changes in material properties
are interrelated with geometric adaptations and contribute to the disease progression until
wall stress exceeds the tensile strength of the arterial tissue and the AAA rupture occurs.
Around 80% of patients with ruptured aorta will not survive this fatal yet preventable event
13

. Current method in determining the severity of AAA is to use the maximum transvers

diameter of abdominal aorta (AA) criterion. However, autopsy reports indicate this current
approach is not a reliable indicator since small aneurysms can also rupture, while many
aneurysms can become very large without rupturing

14

. Furthermore, in majority of

patients, AAA remains to be asymptomatic and often under-diagnosed

13,15

. A more

inclusive approach of evaluating AA that accounts for regional attributes of the disease

2

geometry and changes in mechanical properties, with respect to progression of AAA, can
more accurately match patients with their appropriate treatment options.
Carotid Artery Stenosis
Carotid artery stenosis (CAS) is an atheromatous narrowing of the common carotid
artery or internal carotid artery and is responsible for 10-20% of all strokes 16. The carotid
arteries are major blood vessels, which at their healthy state, carry regulated blood flow
and perfuse the structures of the head and neck. Nevertheless, anatomical anomalies such
as siphons and branching in the different sections of the carotid artery disrupt the blood
flow pattern and generate mechanical forces that cause flow recirculation, consequently,
reduce shear stress/blood flow velocity

17–20

. Such reduction in the wall shear stress or

creation of recirculation patterns cause endothelial dysfunction, which can lead to
modifying the internal vascular structure by accumulation of atherosclerotic plaque. The
progression of atherosclerosis can result in stroke or embolism. Carotid endarterectomy
(CEA) remains the most commonly performed surgical treatment for symptomatic and
asymptomatic carotid atherosclerotic disease

21,22

. Carotid angioplasty with stenting or

other catheter-based treatment options are minimally invasive alternative approaches to
CEA. Since the initial development of these intervention options, clinicians have debated
around whether CEA, endovascular treatment options, or medication therapy alone is most
appropriate in patients with symptomatic and asymptomatic carotid stenosis 16. In recent
years a more selective approach in classification of CAS has attracted attention due to
concerns involving post-endarterectomy restenosis, perioperative risks, and comorbidities
that preclude major operations. Nevertheless in practice, CAS geometry-based risk analysis
is limited to a single-point measured stenotic diameter reduction, which is the backbone

3

current clinical decision making guidelines 7. Current criteria do not account for regional
heterogeneity, which is shown to induce patient-specific variations in hemodynamic and
consequently dissimilar disease severity given the same diameter decrease 16,23,24.
Endovascular Technology – Drug Coated Balloon
Recent advances in endovascular therapies have broaden the options for treating
vascular disease 25,26. Drug-coated balloon (DCB) therapy is an emerging technology and
a case in point here. A DCB consists of a standard angioplasty balloon catheter coated with
an antiproliferative drug. During the DCB procedure, a deflated coated angioplasty balloon
is tracked through arteries using a guide wire to the treatment site, where the DCB is
inflated using an expansive force. Balloon inflation is used to disrupt the atherosclerotic
plaque, delaminate the coating and transfer the therapeutics to the lumen of the artery.
DCBs are currently used to treat various atherosclerosis-induced vascular diseases by
opening up the blocked arteries and delivering antiproliferative therapeutics locally to
prevent restenosis

27–32

. DCB therapy has multiple potential advantages over other

endovascular procedures such as bare-metal stent and drug-coated stent. Primarily, DCB
does not leave an implant in the treatment site, therefore, avoids metal- or polymer-induced
restenosis (renarrowing of arteries) and stent fracture associated with stent implantation or
stent fatigue. In theory, DCBs distribute antiproliferative drugs more homogenously than
stents do and DCBs become more favorable for in-stent restenosis where avoidance of stent
placement is recommended 33. Most DCBs currently available are coated with drugs either
directly without using any excipients (an excipient is an inactive substance that provides a
platform to carry drug on the balloon surface and to deliver it in a controlled manner) or
using different types of excipients 34,35. Most of these excipients are selected based on their

4

utility to improve drug penetration into the tissue. An effective DCB excipient, among
other considerations, provides structural stability as well as promoting favorable physical
or chemical properties of the coating. Currently, there are major limitation related to the
available DCBs, despite the great potential of the treatment. The delivery of drug from the
coated balloons is neither controlled nor adequate in order to avoid drug loss during balloon
tracking, arterial disruption and extended inflation time

34

. It has been reported that a

substantial amount of the initial therapeutic load (up to 80%) is lost in the blood stream
even before the balloon is tracked to the treatment site 34,36. Hence, in many cases, only an
insufficient level of drug is delivered at the treatment site 34,35. Therefore, a pressing need
has arisen to control the delivery of drug from the balloons to the treatment site during the
short time of balloon inflation. A more efficient DCB therapy will allow for lower doses
of initial therapeutic loading, possibly will cause less arterial disruption in the site of
treatment by application of more regulated magnitudes of expansive force.
1.2

HYPOTHESES
Following chapters discuss a series of studies that aim to investigate the role of

geometry in understanding the severity of vascular diseases, clinical decision-making
process and endovascular drug delivery device development 37–40. The central hypotheses
in these studies include the following: 1) Examining isolated and combined effects of local
geometrical descriptors and material properties of idealized AAAs can provide insight into
the contribution of different parameters to AAA rupture risk. 2) Regional hemodynamics
of CAS, and wall shear stress-based disease progression risk can be estimated using a set
of geometric variables of stenotic plaque and parent vessel. 3) A judicious choice of DCB
excipient based on intrinsic geometry of coating can systematically control drug uptake by
5

arterial tissue. 4) Systematic and repeatable manipulation of DCB microstructural
geometry can increase drug transfer, while forming a biocompatible and structurally stable
coating.
1.3

DISSERTATION SCOPE AND SPECIFIC AIMS
Dissertation projects collectively highlighted the significant role of geometry in

vascular disease and an endovascular intervention technology, DCB. For instance, in
evaluating AAA rupture risk both geometric and material properties were considered to
investigate the contribution of each factor in wall stress estimation. Both geometric and
material properties of AAA pathology were found to be significant, yet select key factors
in isolation resulted in more drastic changes in wall stress. In case of carotid artery stenosis,
a diverse set of geometric variables were defined and extracted from medical images of
CAS, and correlations with local hemodynamics were studied. As reported previously,
hemodynamics of CAS can be related to the risk of stroke, embolic events and disease
progression. Therefore, this study focused on developing a framework that can predict
hemodynamics based on patient-specific geometry descriptor without resources necessary
for individual simulations. Finally, microstructural analysis of DCB therapy is another case
in point; where coating contact mechanics and DCB drug excipient geometry were
researched. This work found an association between a DCB procedural factor, application
force, coating intrinsic shape and acute drug transfer. Results of this study inspired more
research in this field in order to increase DCB therapeutic efficacy. Research activities in
this area aim to explore effects of systematic and repeatable changes to DCB surface on
drug transfer, and ultimately identify and produce a more ideal surface characteristics to

6

optimize the DCB therapy with respect to procedural factors including application force
and time.

7

CHAPTER 2
MECHANICAL AND GEOMETRICAL DETERMINANTS OF WALL
STRESS IN ABDOMINAL AORTIC ANEURYSMS: A
COMPUTATIONAL STUDY1

1

Azar D., Ohadi D., Rachev A., Eberth J. F., Uline M. J., Shazly T., 2018. Mechanical
and geometrical determinants of wall stress in abdominal aortic aneurysms: A
computational study. Plos One. 13:e0192032.
DOI: https://doi.org/10.1371/journal.pone.0192032
Reprinted here with permission of publisher.
8

2.1

ABSTRACT
An aortic aneurysm (AA) is a focal dilatation of the aortic wall. Occurrence of AA

rupture is an all too common event that is associated with high levels of patient morbidity
and mortality. The decision to surgically intervene prior to AA rupture is made with
recognition of significant procedural risks, and is primarily based on the maximal diameter
and/or growth rate of the AA. Despite established threshold levels for intervention, rupture
occurs in a notable subset of patients exhibiting sub-critical maximal diameters and/or
growth rates. Therefore, a pressing need remains to identify new predictors of rupture risk
and ultimately integrate their measurement into clinical decision making. In this study, we
use a series of finite element-based computational models that represent a range of
plausible AA scenarios, and evaluate the relative sensitivity of wall stress to geometrical
and mechanical properties of the aneurysmal tissue. Taken together, our findings encourage
an expansion of geometrical parameters considered for rupture risk assessment, and
provide perspective on the degree to which tissue mechanical properties may modulate
peak stress values within aneurysmal tissue.
2.2

INTRODUCTION
A significant manifestation of cardiovascular disease involves a regional dilation

of the aorta termed an aortic aneurysm (AA)

6,41–55

. Diagnosed using ultrasonography,

computed tomography, or magnetic resonance imaging, a segment of the aorta that is found
to be greater than 50% larger than that of a healthy individual of the same sex and age is
considered aneurysmal 56. AA can arise in either the thoracic or abdominal sections, with
current estimates that over a quarter-million new cases of AA occur each year in the United

9

States alone. Thus, several million patients carry the diagnosis of AA, and unfortunately a
significant portion of these patients will either die from rupture or morbidity arising from
complex surgical/endovascular repairs.
While stimuli for AA genesis and progression can be diverse, wall rupture is
ultimately a mechanical failure that occurs when intramural stresses exceed wall strength
11,57

. Intramural stresses generally increase with aneurysm growth and inherently depend

on the applied loads, the geometry and location of the AA, and the mechanical properties
of the aortic wall. Despite the multiple determinants of wall stress, a set-point point of 5.0
– 5.5 cm in diameter is the typical threshold for surgical intervention 46,51. Endovascular or
surgical repair of AA is not without significant costs and complications

6,41,46,47,49,52

.

Therefore, any advancement in terms of assessing the risk of AA rupture would be of high
clinical significance.
Computational modeling utilizing finite element analysis (FEA) is a wellestablished approach to predict wall stresses in the context of AA. Previous studies have
shown that, in addition to maximum AA diameter, centerline tortuosity is a deterministic
parameter in AA rupture risk

58,59

. Other studies have also suggested that indices of AA

surface curvature and wall thickness impact rupture risk

60

, primarily via correlation of

rupture location with geometrical features of the AA 61. The results of any FEA-based study
are highly dependent on the employed material models and distinct domains in which wall
stress is computed. A previous study that assessed ruptured and non-ruptured AA via
computed values of the peak wall stress (PWS) demonstrated that incorporation of various
levels of geometric complexity derived from computed tomography data could
significantly impact obtained results

62

. Thus, if the modeling objective is to generate a

10

patient-specific prediction of wall mechanics in the context of AA, it is likely that highfidelity geometries and accurate material models would be required.
As opposed to generating patient-specific predictions of AA wall mechanics, the
purpose of this study is to compare the isolated and synergistic effects of general geometric
and mechanical properties on AA rupture potential in idealized scenarios. Although both
contribute significantly to the wall stresses experienced by the AA under physiological
loading, only the former is regularly considered in risk analysis with most interventional
criteria focused on diameter measurements alone. We systematically explore certain
geometrical characteristics descriptive of AA (i.e., location within the parent vessel,
axial/circumferential extent, thickness, and tortuosity) which may significantly increase
mural stress levels and thereby warrant an elevated risk status for the patient. While
noninvasive measurement of AA mechanical properties is admittedly limited, we utilize
established constitutive models and prior studies to provide reasonable estimates of
baseline mechanical properties. Thus we explore the potential for the use of representative
mechanical properties, in combination with diverse but accessible measurements of AA
geometric properties, as a basis for risk evaluation 63–65.
2.3

METHODS
Overview

A series of finite-element based computational models of human

abdominal aorta that are based on classic continuum mechanics were developed to quantify
the wall stress field in the context of abdominal aortic aneurysm (AAA) under
normotensive conditions. The premise of our study is that while the deformed diameter of
AAA is the clinical standard for estimating rupture risk, other AAA characteristics may be
useful in predicting local elevations in wall stress. Computational parametric studies were
11

designed to isolate the dependence of wall stress on aneurysm geometry/location and tissue
mechanical properties; the interactive effects of select characteristics on wall stress were
also analyzed. Two response variables were extracted from each simulation, namely the
average and peak Von Mises stress within the aneurysmal region.
2.3.1

Referent Normal Aortic Geometry
The constructed geometry of the abdominal aorta and the aortic bifurcation were

based on previous anatomical examinations

66

. Three-dimensional (3-D) geometrical

models of the aorta (with and without AAA) were generated using CATIA V5R21 CAD
software. All models entail a symmetric aorta-iliac bifurcation and common iliac arteries.
The referent normal aortic geometry has dimensions: length (L) of 120 mm; outer diameter
(D) of 20 mm; uniform wall thickness (t) of 2 mm (Figure 2.1A-B). The proximal diameter
of the iliac arteries is 13 mm and gradually decreases to 10.3 mm over the considered length
of these vessels (42 mm). The take-off angle of the iliac arteries at the bifurcation (α) and
the angle between the aortic centerline and the plane formed by both iliac arteries (β), are
20° and 15°, respectively. The radii of curvature at the aorta-iliac junction is 50 mm on
both sides.
2.3.2

AAA Geometric Parameters
Geometric parameters used to characterize AAAs are defined with reference to

cross-sectional planes (CS0 – CS8) spanning the longitudinal section of the aorta as
follows: axial and circumferential extent of the AAA region, axial location of the AAA
region, maximum transverse outer diameter of AAA region, local wall thickness and
centerline tortuosity of the AAA region (Figure 2.1C-D). The baseline values and

12

examined range for each geometric parameter (described below) were motivated by clinical
observations of AAA (Table 2.1).
2.3.3

AAA Geometry
The longitudinal length of the aorta considered for geometric variation (L*) is 128

mm and is defined by nine cross-sections (CS0 – CS8) that are parallel to XY-plane (Figure
2.1C). To impart geometric variations reflective of AAA and enable parametric
computational studies, CS0 – CS8 were systematically manipulated and then closed splines
connecting their perimeters were applied to define outer and inner surfaces. For the
baseline AAA geometry, outer closed splines on CS1 and CS2 are circles (corresponding
to a 360° circumferential extent) with a diameter of 45 mm; wall thickness smoothly
decreases from its referent normal value of 2 mm to 1.50 mm on CS1 and CS2. All other
CSs remained unchanged with respect to the previously generated referent normal aortic
geometry, with the exception of CS3, which was left free of constraints to produce a smooth
evolution of surfaces. The midway plan of the baseline AAA sac is located 32 mm from
CS0 (Figure 2.1C-D).
For sensitivity analyses, each geometrical parameter was varied in isolation over
physiologically-relevant ranges as follows: AAA location via the center of the AAA sac
along the Z-axis; wall thickness via the inner splines on CS1 and CS2; maximum AAA
diameter via inner and outer splines on CS1 and CS2; tortuosity in XZ- and YZ- planes via
the centers of inner and outer circles on CS1 and CS2; axial extent via the number of CS
planes included within AAA sac; the circumferential extent of the AAA sac via progressive
reduction of the anterior quarter of CS1 and CS2 by 90° (Figure 2.2).

13

2.3.4

Mechanical Properties of the Referent Normal Aorta
The mechanical properties of aortic tissue were quantified using a previously

" is
developed structure-motivated constitutive model, where the strain energy function ψ
" !"# and anisotropic term ψ
" $%!"# ,
the sum of an isotropic term ψ
"=ψ
" !"# (𝐼&̅ ) + ψ
" $%!"# (𝐼'̅ , 𝐼(̅ )
ψ

(2.1)

and 𝐼&̅ , 𝐼'̅ , 𝑎𝑛𝑑 𝐼(̅ are invariants of the right Cauchy-Green strain tensor

67,68

. A neo-

" !"# with the following analytical form,
Hookean material model is used for ψ
" !"# (𝐼&̅ ) =
ψ

)
*

(𝐼&̅ − 3)

(2.2)

where µ has the dimension of stress and is the only material parameter 67. A sum of two
" $%!"# , which describes the strain energy stored by two
exponential function is used for ψ
symmetrically-oriented collagen fiber families with respect to the vessel longitudinal axis.
" $%!"# has the following analytical form,
ψ
" $%!"# (𝐼'̅ , 𝐼(̅ ) =
ψ

+!
*+"

∑!,',({exp[ 𝑘* (𝐼!̅ − 1)* ] − 1}

(2.3)

where the invariants 𝐼'̅ and 𝐼(̅ correlate with the square of the stretches of two fiber families
in their respective directions. Moreover, k1 > 0 is a material parameter with units of stress
and k2 > 0 is dimensionless 67. The referent normal values for all material parameters (Table
2.2) are based on previous ex-vivo mechanical studies of aortic tissue 69.
2.3.5

Mechanical Properties of Aneurysmal Tissue
Within the constitutive framework provided by (Equations 2.1-2.3), Pierce et al.

estimated material parameters for eight human AAA samples 70. The fitted values for all
material parameters informed our specification of baseline AAA as well as the examined

14

ranges in parametric studies (Table 2.3). In all AAA simulations, collagen fiber angle was
fixed at 45°and no fiber dispersion factor was applied.
2.3.6

Meshing, Boundary Conditions and Solving
Generated 3-D geometries were meshed using Altair HyperMesh v12.0 software

package via first order hybrid tetrahedral elements. Tetrahedral elements were selected for
meshing to avoid elemental collapse in model geometries with high curvature regions 71,72.
Mesh independency studies were performed on both the referent normal and baseline AAA
geometries, wherein simulation results were deemed mesh-independent if additional mesh
refinement led to a less than 4% change in both the peak and average von Mises stress. A
total of 289,762 tetrahedral elements were required for mesh-independency, which set the
minimum meshing threshold for all parametric studies. Boundary conditions were applied
to the meshed geometries using a FEBio Software package pre-processor, PreView. A
uniform pressure of 120mmHg (0.016 MPa) was applied to the vessel inner surface via a
gradual ramping up from zero pressure. The presented results thus refer to a stationary
solution. A complete motion constraint (displacement and rotation) at all vessel
initiation/termination surfaces were applied to facilitate solution convergence. All studies
were performed with the full Newtonian solver settings in FEBio FEA open-source
software 73.
2.3.7

Post-processing of Computational Data
The direct output of all simulations (displacement vector field) was transformed

using FEBio post-processor, PostView, with computed response variables including peak
von Mises wall stress (PWS) and average von Mises wall stress (AWS) within the
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aneurysmal sac (or analogous location for the referent normal aorta). For calculation of
AWS, obtained values were weighted by element size (area-weighted average stress).
2.4

RESULTS

2.4.1

Wall Stress in the Referent Normal Aorta
Colorimetric surface plots (without gradient smoothing, anterior and posterior

views) of the von Mises stress in the referent normal aorta reveal a relatively uniform wall
stress distribution until the aortic bifurcation, with AWS of 0.013 MPa. A notable elevation
in wall stress occurs at the aortic bifurcation, with a PWS of 0.091 MPa. Continuity of the
von Mises stress field extending from the model boundaries qualitatively suggests that edge
effects are minimized in the referent normal simulation (Figure 2.3A).
2.4.2

Wall Stress in AAA
Analogous surface plots of the von Mises stress field in the baseline AAA show a

nonuniform wall stress distribution in comparison to the referent normal aorta. (Figure
2.3B). The AWS within the aneurysmal sac is 0.11 MPa, while a PWS of 0.76 MPa occurs
near the sac center point. While stress values generally exhibit an order-of-magnitude
increase in the baseline AAA as compared to the referent normal aorta, the PWS remains
below the assumed ultimate strength (1 MPa) of aortic tissue 74 (discussed below).
2.4.2.1 Effects of AAA Geometry
A series of simulations were performed under isolated variation of geometric
parameters with respect to the baseline AAA model. AWS and PWS computed throughout
these parametric studies reveal the relative sensitivity of wall mechanics to distinct
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morphological features (Figure 2.4A-G). In all parametric sweeps, the percent variability
in AWS over the examined range is reduced in comparison to that of PWS.
In terms of AAA axial extent, the largest value (96 mm) induces the greatest stress
levels (Figure 2.4A). Interestingly, decreasing the axial extent with respect to the baseline
AAA value (64 mm → 48 mm) also results in an increase in PWS; this is understood as a
local consequence of increased sac curvature in proximity to the aortic bifurcation.
Variation in AAA circumferential extent, as defined in this study, also has a non-monotonic
effect on PWS (Figure 2.4B). In this case, a 270° circumferential extent of the sac causes
an approximately 30% increase in PWS as compared to the baseline AAA case
(circumferential extent of 360°); this is a consequence of sac asymmetry and the resultant
increase in local curvature on the posterior sac surface. For all other examined scenarios,
both PWS and AWS exhibit a monotonic response to isolated manipulation of the defined
geometric parameters (Figure 2.4C-G). Among these, the most deterministic parameters
are clearly sac diameter (Figure 2.4C) and wall thickness (Figure 2.4E), for which maximal
percent changes in PWS with respect to baseline AAA are 231% and 457%, respectively
(Table 2.4).
2.4.2.2 Effects of AAA Mechanical Properties
A second series of parametric studies entails isolated manipulations of the AAA
mechanical properties with respect to the baseline AAA model. (Figure 2.5A-C). As with
geometrically-focused parametric sweeps, the percent variability in AWS over the
examined range is reduced in comparison to that of PWS. PWS was notably more sensitive
to mechanical properties associated with the anisotropic (as opposed to isotropic)
" $%!"# ), with k1 and k2 inducing a maximal
component of the strain energy function (ψ
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percent changes in PWS with respect to baseline AAA of 314% and 156%, respectively
(Table 2.4).
2.4.2.3 Interactive Effects of AAA Properties
A third series of parametric studies examines the relative change in sensitivity of
PWS to select AAA geometrical and mechanical properties with progressively increasing
sac diameter (Figure 2.6). In the case of wall thickness, a 50% reduction (2 mm → 1 mm)
leads to an increase in PWS that is approximately 1 MPa when the sac diameter is 35 mm,
and 2 MPa when the sac diameter is 70 mm (Figure 2.6A). Comparatively, a 50% increase
in AAA axial extent (64 mm → 96 mm) leads to an increase in PWS that is less than 0.02
MPa when the sac diameter is 35 mm, but over 2 MPa when the sac diameter is 70 mm
(Figure 2.6B). An even more significant interactive effect occurs when diameter changes
in tandem with AAA mechanical properties. When computed over the examined range of
material parameter K1, the change in PWS is approximately 1.5 MPa at a sac diameter of
35 mm but increased to nearly 6 MPa at a sac diameter of 70 mm (Figure 2.6C).
2.5

DISCUSSION
The aim of this study is to apply finite element-based computational modeling to

gain insight on the relative degree to which geometrical and mechanical properties of AAA
determine the AWS and PWS within the aneurysmal sac. Potential interactive effects
between select properties are also analyzed. In a similar computational model by Raghavan
et al., the PWS computed for a referent normal aorta (diameter = 20 mm) was 0.12 MPa,
which is close to our obtained value (0.091 MPa) 63. As a benchmark for our baseline AAA
model, we compared our results to findings by Roy et al. in which a model with similar

18

geometry/properties exhibited a PWS of 0.76 MPa

75

. In the same study, they also

considered patient-specific geometries and found a maximum principal stress of 0.79 MPa
in a mid-sized AAA 75. The reported values for PWS in these representative AAA scenarios
are close to our findings in the baseline AAA model (PWS of 0.76 MPa). Finally,
Rodriguez et al. developed a representative AAA model and computed a maximum
principal wall stress of 0.79 MPa, which is close in value to the PWS obtain by us and
others. Analyses of peak von Mises stress and maximum principal wall stress across these
studies is justified by the relatively low values of shear stresses within the vessel wall seen
in our study and reported in others 76.
Aneurysmal sac rupture theoretically occurs when peak wall stress exceeds the
ultimate strength of the vascular tissue. In line with this notion, it is not surprising that wall
stress can predict sac rupture better maximum diameter 77,78. To facilitate the quantification
of rupture risk, numerous studies have sought to identify the ultimate tissue strength in
AAA, wherein Giannoglu (2006) reported a median value of 1.23 MPa and Vande Geest
et al. predicted values ranging from 0.54 MPa to 1.43 MPa 59,79. Similarly, others suggest
failure stresses on the order of 1MPa

74,80

. For the purposes of subsequent discussion, we

consider the ultimate strength of the AAA wall to be 1 MPa.
Obtained results confirm that wall stress is highly sensitive to sac diameter (Figure
2.3C, Table 2.4), thereby supporting the established clinical approach of monitoring
maximal sac diameter and its expansion rate for estimation of rupture risk. Our model
predicts that as sac diameter reaches the standard clinical threshold for surgical intervention
(5.0 – 5.5 cm), PWS is near/above the assumed ultimate strength of aortic tissue (1 MPa).
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Moreover, increasing diameter above this threshold leads to a dramatic increase in PWS,
supporting the need for immediate surgical intervention to prevent rupture.
Although many previous computational studies use uniform wall thickness to
predict AAA mechanics 58,77,81–85, it is intuitively obvious that an isolated reduction in wall
thickness will increase PWS within the aneurysmal sac. The choice to maintain a uniform
wall thickness close to the baseline value is supported by some previous studies, in which
AAA wall thickness was measured to be near its referent normal value 61,86. Therefore, our
predicted PWS response to varying wall thickness (Figure 2.4E) may not be applicable to
all instances of AAA; rather, our results provide clinical motivation to monitor wall
thickness as a precautionary measure. Indeed, a significant fraction (13%) of AAAs under
5 cm in diameter rupture 87, underscoring the need to identify additional risk factors beyond
maximal sac diameter/expansion rate. Of the previous studies that did examine AAA wall
thickness, Venkatasubramaniam et al. predicted that increasing/decreasing wall thickness
by 25% leads to nearly a 20% decrease/increase in PWS, respectively 83. In a multivariate
study, Celi et al. (2010) showed that an AAA characterized by a relatively larger diameter
and uniform thickness would exhibit reduced PWS compared to an AAA with a smaller
diameter and reduced wall thickness 8. In our study, PWS was the most sensitive to wall
thickness among the explored parameter space, which therefore supports its consideration
as a key factor in clinical risk assessment.
Previous studies have demonstrated that as the axial extent of the AAA increases,
PWS also increases 60,81. While our results are in line with this expectation for axial extents
exceeding the baseline AAA value (above 64 mm), we also predict an increase in PWS at
exceedingly low levels (48 mm). We speculate that this latter effect is a consequence on
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enhanced surface curvature in the distal portion of the AAA combined with the proximity
to the aortic bifurcation. Indeed, Venkatasubramaniam et al. concluded that overall shape
and sac asymmetry are significant determinants of AAA wall stress 83. Other studies have
developed various methods to interrelate sac asymmetry to wall stress levels, and in all
cases concluded a positive correlation between the two 81,88–90.
AAA asymmetry can be magnified by increased tortuosity, which is a recognized
geometric determinant of not only wall stress but also intra-aneurysmal flow patterns and
resultant flow-induced shear stresses

58,59,81,91–95

. In our parametric sweeps, the applied

tortuosity variation in either the XZ or YZ planes was modest in comparison to these and
other previous studies due to the increased complexity of surface assignment. Nevertheless,
PWS exceeding the tissue ultimate strength was observed within our examined range (Fig
4F and G). Although not realized in this study, we expect that additional increase of AAA
tortuosity would lead to even greater PWS values.
Despite containing parametric sweeps focused on AAA mechanical properties
within reported ranges for AAA tissue, it is important to note that isolated property
manipulation in this sense may create a scenario (set of mechanical properties) that is not
reflective of aneurysmal (or referent normal) tissue. Nevertheless, computed changes in
AWS and PWS compared to those observed with geometric sweeps enable qualitative
speculation on the relative impact of geometrical versus mechanical properties on AAA
mechanics. Based on the notable percent change in PWS (314%) predicted for variation of
k1, we conclude that material and geometrical properties are potentially equally
deterministic of PWS.
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2.5.1

Study limitations
The conclusions drawn in this study should be considered along with some study

limitations. Firstly, all simulations were performed under normotensive conditions,
although some AAA patients often also present hypertension. Clearly the application of
higher values of pressure in our model (to simulate a hypertensive state) would result in
different (higher) peak wall stress 96. However, we specifically want to draw attention to
cases where clinically-determined geometric parameters, most notably the maximal AAA
diameter, are beneath established thresholds for intervention but wall stress is elevated
beyond a critical limit. We believe this analysis is more relevant under normotensive
conditions where the impetus for surgical intervention is nominally lower, motivating our
selection of the applied pressure boundary condition. Secondly, our simulations were
carried out in the framework of classical continuum solid mechanics, and therefore ignore
the potential for flow-induced shear stress on the inner vessel surface to impact AAA
rupture risk, as pursued in previous studies 58,60,61,75,81,97. Thirdly, the ultimate strength of
vascular tissue is patient-specific and would vary with age and disease states, wherein our
analyses assumed a single, representative ultimate strength of 1 MPa based on the range of
values found in the literature 74. Finally, the ranges of geometries and material properties
explored in our study are based on idealized scenarios rather than patient-specific
characteristics, which limits the translational significance of our findings. However, rather
than evaluating actual clinical scenarios, the aim of this study is to identify general
(idealized) determinants of PWS that can be introduced into risk evaluation irrespective of
patient-to-patient differences.
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2.5.2

Conclusion
The predicted interactive effects of sac diameter with thickness, axial extent, and

material parameter k1 accentuate the need for integration of additional risk factors into
clinical decision making. Even with the few potential interactions considered in this study,
it is evident that PWS values above the ultimate tissue strength are readily attainable in the
sub-critical diameter range (< 5.0 cm). Taken together, our findings encourage an
expansion of AAA parameters considered for clinical risk assessment and decision making
and demonstrate the potential for computational modeling to further elucidate key factors
governing AAA mechanics.
2.6
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Table 2.1: Geometric parameter values for the baseline AAA (underlined) and
associated parametric studies.
Axial extent Circumferential Diameter1 Location on Thickness Tortuosity Tortuosity
[mm]
[mm] Z-axis2 [mm] [mm]
XZ-plane YZ-plane
extent [°]
48

90

35

32

0.75

-1.175

-1.175

64*

180

40

48

1.00

-1.05

-1.05

80

270

45

64

1.25

1.00

1.00

96

360

50

1.50

+1.05

+1.05

55

1.75

+1.175

+1.175

60

2.00

65
70
1

Maximum transverse diameter

2

Distance from the bottom-most-cross-section (CS0) to the midway plane of aneurysmal
sac in positive Z-direction
*

Values underlined are geometrical input parameters defining the baseline AAA

Table 2.2: Mechanical properties for referent normal aortic tissue.
µ [MPa]

k1 [MPa]

k2

j [°]

0.007

2.87

17.26

36.0
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Table 2.3. Mechanical property values for the baseline AAA (underlined) and
associated parametric studies.
µ [MPa]

k1 [MPa]

k2

j [°]

0.001

1.00

0.001

45.0*

0.004

1.50

1

0.009

2.00

30

0.013**

2.74

70

0.017

6.00

119.6

0.040

15.00

350

0.085

50.00

500

0.100
*

Fiber angle of 45.0° was applied to all aneurysmal models

**

Values underlined are material input parameters defining the baseline AAA case

Table 2.4. Sensitivity of PWS to geometrical and mechanical parameters
characterizing AAA.
Parameter

Referent
normal

Baseline
AA

Range of input
parameter

Percentage
change in PWS3

µ [MPa]

0.007

0.013

[0.001,0.1]

22.0%

k1 [MPa]

2.87

2.74

[1,50]

314%

k2

17.26

119

[0.001,500]

156%

Axial extent [mm]

N/A

64

[48,96]

172%

Circumferential extent [°]

N/A

360

[90,360]

88.1%

Diameter1 [mm]

20

45

[35,70]

231%

Location on Z-axis2 [mm]

N/A

32

[32,64]

9.06%

Thickness [mm]

2.0

1.50

[0.75,2.00]

457%

Tortuosity XZ-plane

1

1

[-1.175,1.175]

62.1%

Tortuosity YZ-plane

1

1

[-1.175,1.175]

112%

1

Maximum transverse diameter

2

Distance from the bottom-most cross-section (CS0) to the midway plane of aneurysmal
sac in positive Z-direction
3

Maximum percentage change over examined range with respect to baseline AAA value
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Figure 2.1: Referent normal aortic and baseline AAA geometries.
(A) Referent normal aortic geometry in XZ- and YZ-planes; L is the length of abdominal
aorta, D is the outer diameter, t is the thickness, Rc is the radius of curvature, Li is the
length of common iliac arteries, α and β are the take-off angle of the iliac arteries at the
bifurcation and the angle between the abdominal aorta centerline and the plane formed by
both iliac arteries, respectively. (B) An isometric view of the referent normal aortic
geometry. (C) Baseline AAA geometry in XZ- and YZ-planes; L* is the length of
geometrical variations field, CS0-8 are cross-sectional planes formed by dividing field of
geometrical variations into eight sections longitudinally. (D) An isometric view of baseline
26

AAA geometry and depiction of geometrical input variables; t is the thickness within the
aneurysmal sac, Dia. is the maximum transverse outer diameter of the aneurysmal sac, Cir.
depicts the circumferential extent of the aneurysmal sac, Tort. indicates the tortuosity in
XZ and YZ-planes, Axi. and Loc. are the axial extent and the longitudinal location of
aneurysmal sac, respectively.

Figure 2.2: Circumferential (angular) extent of AAA bulging.
Top views of a (A) 90° (B) 180°, (C) 270° sweep and (D) 360° sweep on anterior face of
aneurysmal sac.
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Figure 2.3: Predicted von Mises wall stress.
Computed von Mises wall stress distributions for (A) referent normal aorta and (B) baseline
AAA simulations. (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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Figure 2.4: Effects of AAA geometrical properties.
PWS (black) and AWS (grey) are computed over isolated variations of defined AAA
geometrical properties, including (A) axial extent, (B) circumferential extent, (C)
maximum sac diameter, (D) sac location, (E) wall thickness, (F) tortuosity in XZ plane,
and (G) tortuosity in YZ plane. In all cases, hollow square markers indicate the baseline
AAA values.
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Figure 2.5: Effects of AAA mechanical properties.
PWS (black) and AWS (grey) are computed over isolated variations of defined AAA
mechanical properties, including (A) µ, (B) k1, and (C) k2. In all cases, hollow square
markers indicate the baseline AAA values.
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Figure 2.6: Interactive effects of geometrical and mechanical properties.
PWS as a function of sac diameter and prescribed levels of (A) wall thickness, (B) axial
extent, and (C) K1. The size of bars containing data points at a given diameter reflect the
sensitivity of PWS to each parameter.
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CHAPTER 3
GEOMETRIC DETERMINANTS OF LOCAL HEMODYNAMICS IN
SEVERE CAROTID ARTERY STENOSIS2

2
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3.1

ABSTRACT
In cases of severe carotid artery stenosis (CAS), carotid endarterectomy (CEA) is

performed to recover lumen patency and alleviate stroke risk. Under current guidelines, the
decision to surgically intervene relies primarily on the percent loss of native arterial lumen
diameter within the stenotic region (i.e. the degree of stenosis). An underlying premise is
that the degree of stenosis modulates flow-induced wall shear stress elevations at the lesion
site, and thus indicates plaque rupture potential and stroke risk. Here, we conduct a
retrospective study on pre-CEA computed tomography angiography (CTA) images from
50 patients with severe internal CAS (>60% stenosis) to better understand the influence of
plaque and local vessel geometry on local hemodynamics, with geometrical descriptors
that extend beyond the degree of stenosis. We first processed CTA images to define a set
of multipoint geometric metrics characterizing the stenosed region, and next performed
computational fluid dynamics simulations to quantify local wall shear stress and associated
hemodynamic metrics. Correlation and regression analyses were used to relate obtained
geometric and hemodynamic metrics, with inclusion of patient sub-classification based on
the degree of stenosis. Our results suggest that in the context of severe CAS, prediction of
shear stress-based metrics can be enhanced by consideration of readily available,
multipoint geometric metrics in addition to the degree of stenosis.
3.2

INTRODUCTION
Carotid artery interventions, such as carotid endarterectomy (CEA) and carotid

artery stenting, have been used for over half a century to reduce stroke risk in patients
presenting with severe carotid artery stenosis (CAS). However, these interventions carry
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an aggregate complication rate of 4.5%–7.0%, with potential negative outcomes including
myocardial infarction, pulmonary embolism, and post-operative stroke

98–100

. Clinical

observations and experimental studies have demonstrated the importance of plaque
geometry on local hemodynamics and embolic potential, motivating consideration of the
degree of vessel stenosis in clinical decision making 37,101–104. Current guidelines for CEA
from most major international bodies recommend intervention for neurologically
symptomatic CAS with ≥ 70% diameter reduction in the internal carotid artery (ICA),
while others use a threshold of ≥ 50% diameter reduction

16,105

. Clinical guidelines

recommend that in these cases, surgery is performed within two weeks of the onset of
neurological symptoms 106. Existing guidelines for neurologically asymptomatic cases are
less uniform, but clinical decision-making still depends mainly on the maximum degree of
stenosis 16,106. In addition to the degree of stenosis, higher fidelity geometric details of the
atherosclerotic plaque and parent vessel are accessible via clinical imaging including
computed tomography angiography (CTA), and have been shown to significantly impact
the local blood flow field and plaque mechanics 24,107–109. For instance, an increase in lesion
axial length is inversely related to axial plaque stress in severely stenotic cases (≥60%),
thus suggesting extended lesions have relatively diminished embolic potential 24. Plaque
asymmetry in the stenosed region has also been shown to impact local wall shear stress
magnitudes and flow recirculation patterns

107,110

. Other studies have found correlation

between vessel tortuosity and flow-dependent pressure gradients, with a co-dependence on
the degree of stenosis

111

. In a study that examined both degree of stenosis and plaque

eccentricity, these factors exhibited a strong interactive effect on the wall shear stress
distribution

112

. In these and other studies, finite element-based computational fluid
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dynamics (CFD) models were used to interrelate plaque geometry and local hemodynamics
23,37,113,114

.

Clinical integration of CFD models requires a noninvasive, image-based
assessment of plaque and vessel geometry and estimation of inlet/outlet blood
velocities/pressures in a control volume encompassing the diseased vasculature. CFD
solutions provide three-dimensional transient velocity/pressure fields and enable
quantification of multiple hemodynamic metrics. These metrics include: flow-induced wall
shear stress (WSS) – the tangential friction force on the endothelial or plaque surface;
oscillatory shear index (OSI) – the temporal fluctuation of the WSS; and relative residence
time (RRT) – the relative dynamic measure of local nonadherent particles within the flow
field. These metrics have been linked to plaque accumulation, remodeling, and rupture risk
10,115

.
The goal of the present study was to process pre-CEA CTA images to define and

quantify multipoint descriptors of lesion geometry, and then build CFD models to compute
hemodynamic metrics at the lesion site. Our hypothesis is that multiple metrics of lesion
geometry, including but not limited to the degree of stenosis, will interactively modulate
local hemodynamics in stenotic carotid arteries.
3.3

METHODS

3.3.1

Patient-specific data acquisition
Fifty de-identified CTA images in DICOM format were obtained from patients with

highly stenotic ICAs evaluated for CEA (Greenville Health System, Greenville, SC).
According to the North American Symptomatic Carotid Endarterectomy Trial (NASCET)
criteria, all cases were at a high risk of stroke with the degree of stenosis ranging from
35

67.4% to 99.1%. Handling and processing of patient images were performed in accordance
with institutional ethics committee guidelines. All patients gave informed consent for use
of their clinical imaging studies under IRB protocol (Pro00027940).
3.3.2

Geometry reconstruction and analysis

3.3.2.1 Reconstruction of patient-specific geometries
A semi-automated approach was developed to efficiently reconstruct the 3D arterial
lumen and identify patient-specific geometric variables of the plaque and local vasculature
(elaborated upon in subsequent sections). This semi-automated process yielded
reproducible assessments independent of operator variability while minimizing time and
resource consumption. The CTA volume is represented in a series of 2D images with a
known distance between each image. A segmentation protocol was established using the
Vascular Modeling Toolkit (VMTK; www.vmtk.org), an open-source pre-processing
resource, to identify the boundaries of the arterial lumen for each slice of the scan using
the distinct density-dependent voxel intensities between the angiography contrast dye and
the plaque/arterial wall. The underlying algorithm in this automated process is based on an
identification of centerlines and a robust decomposition of the bifurcation into its
constituent branches, followed by mapping the surface of each of the branches onto the
parametric plane 116. After manual selection of a seed point and definition of bounds, the
boundaries of the arterial lumen were detected and smoothing algorithms were applied to
remove fine-scale irregularities from the reconstructed surface. Finally, a non-uniform
rational b-spline was then fit to the surface to facilitate domain discretization for CFD
analysis (Figure 3.1A).
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Reconstructed domains were imported into the ANSYS ICEM-CFD meshing
software and fit with a linear tetrahedral surface mesh using a robust octree formulation
117–119

. After smoothing this mesh to increase the quality of the individual elements, a

tetrahedral volume mesh was generated using a Delauney formulation 110,114. Finally, the
arterial wall was fit with a triple layer of post-inflation hexahedral prism elements to allow
for a more accurate capture of the hemodynamics in the boundary layer.
3.3.2.2 Calculation of geometric variables
A MATLAB code was developed to extract the centerline along the vessel
geometry and the cross-sectional area function (A(x)) at every point along the centerline
path 116. A(x) was computed based on normal cross-sections of maximal inscribed spheres
along the centerline. Geometric variables (described below) were calculated from A(x)
center-point coordinates and the associated function value. The region of interest (ROI) for
geometric variable calculation was a 5 mm radius sphere with a center point coincident
with the maximal degree of stenosis (Smax) (Figure 3.1B). The employed ROI sphere radius
(5 mm) was motivated by typical lesion length (along the centerline) across the entire study
cohort. Shear stress and related metrics (discussed in below sections) were temporally- and
spatially-averaged within the ROI to minimize response variable sensitivity to model
discretization.
A set of nine geometric variables were extracted from the reconstructed geometries
to describe the complex geometry of the ROI. Degree of stenosis, S, is the ratio between
the minimal lumen area within the ROI and the proximal lumen area of the non-diseased
section of the common carotid artery. For subsequent analyses, cases were subclassified
based on the degree of stenosis (0.67 < S < 0.80, 0.80 ≤ S < 0.90 and 0.90 ≤ S < 1.00; where
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S×100 corresponds to the percentage of stenosis). Proximal tortuosity, 𝜏. , and distal
tortuosity, 𝜏/ , are the ratios of the centerline path length divided by the point-to-point
distances from Smax to the proximal and distal ends of the ROI, respectively. Proximal
luminal concavity, 𝐶. , and distal luminal concavity, 𝐶/ , are the absolute values of the
second derivative of A(x) with respect to proximal/distal locations (x). A(x) is a quadratic
function that returns the lumen area at the position x defined with respect to the location of
Smax. Proximal area-averaged slope, 𝑚
" . , and distal area-averaged slope, 𝑚
" / , are the
integrals of the first derivative of A(x) with respect to distance divided by the area function
in either proximal and distal sides of the Smax, respectively. Stenosis-to-proximal-end slope
𝑚. , and distal-end-to-stenosis slope, 𝑚/ , are the absolute values of the change in lumen
area over end-to-end distance (Table 3.1).
3.3.3

CFD model construction
CFD models were developed with a finite volume-based Navier- Stokes solver

(ANSYS-Fluent v. 17.2), and each model was run over three cardiac cycles under an
assumption of laminar flow

120,121

. The results presented here refer to averages obtained

over the third cardiac cycle in order to minimize the influence of initial flow conditions.
The blood was characterized as an incompressible non-Newtonian Carreau fluid (h0=0.25
Pa∙s; h∞=0.0035 Pa∙s; λ=25; n=0.25) with a constant density of 1060 kg/m3 and zero-slip
boundary conditions were applied to the rigid arterial walls

121

. A previously acquired

carotid artery velocity profile attained from a healthy human male subject was converted
to a continuous function using a Fourier transform and then used as an inlet velocity
boundary condition on the proximal segment of the common carotid artery (CCA) 122–125.
A fully developed velocity profile was established within 2 cm downstream of the inlet
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across all cases. In accordance with prior studies on highly stenoses carotid arteries,
uniform pressures of 70 mmHg and 90 mmHg were prescribed to the internal and external
carotid artery outlets, respectively

126

. A mesh-independent solution was identified in a

subset of cases (5) as the lowest mesh density for which subsequently increasing density
(>30% increase in total number of elements) did not significantly alter the computed peak
WSS value (<1% change). Based on these studies, a minimum of 100,000 elements
spanning the 8 cm length of the reconstructed carotid bifurcation was used in all models.
3.3.4

Post-processing

3.3.4.1 Hemodynamic response variables
To calculate time-averaged wall shear stress (TAWSS), the instantaneous WSS was
calculated and then averaged spatially/temporally across all elements in the ROI over the
third cardiac cycle:
&

0

TAWSS = 0 ∫1 |𝑊𝑆𝑆| 𝑑𝑡

(3.1)

Mean oscillatory shear index (OSI) is a dimensionless parameter ranging from 0 to
0.5 that is defined based on the temporal fluctuation of WSS and averaged over the ROI,
as:
#

OSI = 0.5 K1 −

2∫$ 455 782
#

∫$ |455| 78

L

(3.2)

where T is the elapsed time and WSS is the magnitude at each individual node.
Mean relative residence time (RRT) considers both the averaged WSS and mean OSI:
&

RRT = :;<==(&?* @=A) =

&
#
2∫$ 455

782

(3.3)

with values reported in Pa-1. RRT reflects the residence time of blood in contact
with or near the endothelium and is considered an important factor in plaque genesis 121.
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3.3.4.2 Statistical analyses
Data were analyzed using MATLAB to identify correlations between geometric
and hemodynamic variables, with Spearman correlation used to quantify correlation
strength and significance. Correlation analyses were carried for all cases together (general
approach) or a piecewise approach that was based on a sub-classification of cases via
degree of stenosis (0.67 < S < 0.80, 0.80 ≤ S < 0.90 and 0.90 ≤ S < 1.00). Geometrical
variables with statistically significant correlation to a given CFD hemodynamic variable
were then used to develop predictive regression models that consider the former as input
and the latter as output. Backward stepwise multiple linear regression was performed for
model parameter identification, with inclusion of variable interactions only if model R2
was increased by > 0.05 due to the inclusion. Regression models were developed based on
either the entire sample set (general regression) or over the defined sub-classification
ranges (piecewise regression). Of the 50 CTA images, 45 were used for regression model
parameter identification, and 5 were reserved for evaluating the predictive capability of the
regression models by comparing predicted values of hemodynamic response variables
against obtained CFD results.
3.4

RESULTS
CTA-based vessel geometric models were used to extract geometric variables (9

per case) using the aforementioned semi-automated approach. Geometric models were also
used in CFD simulations that compute local hemodynamic response variables derived from
WSS (3 per case). Descriptive statistics for geometrical variables and CFD-based
hemodynamic variables are shown in Figure 3.2. Three representative cases from each sub-
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classifications of the degree of stenosis are shown along with the distribution of
hemodynamic variables relative to the degree of stenosis (Figure 3.3)
3.4.1

Simulation results and correlation: TAWSS
Computational simulations qualitatively show an increase in TAWSS magnitudes

with increasing degree of stenosis, with clearly nonuniform stress distributions both
proximal and distal to the bifurcation point (Figure 3.3A). Within these cases of severe
CAS, TAWSS was generally elevated with increasing degree of stenosis. However, an
exponential regression model was statistically insignificant when applied across all cases
(R2 = 0.52; p = 0.14), motivating consideration of additional geometric variables to predict
shear stress and related metrics. When sub-classified based on the degree of stenosis,
TAWSS is relatively more sensitive to increased stenosis in the severe cases (0.90 ≤ S <
1.00); with averaged values of 17.81 ± 16.05 Pa, 29.74 ± 15.95 Pa and 118.72 ± 117.71 Pa
for 0.67 < S < 0.80, 0.80 ≤ S < 0.90 and 0.90 ≤ S < 1.00, respectively (Figure 3.3A). While
a general correlation analysis revealed a positive correlation between TAWSS and the
degree of stenosis, as well as both proximal and distal area-averaged slopes, the
significance of these factors was not fully maintained throughout piecewise correlation
analysis (Figure 3.4). Most notably, no correlation between TAWSS and the degree of
stenosis was observed in the intermediate stenosis subclassification (0.80 ≤ S < 0.90).
3.4.2

Simulation results and correlation: OSI and RRT
Representative colorimetric plots of OSI and RRT underscore the inherent relation

between these flow field metrics, with obvious coincidence of vessel regions experiencing
locally elevated values (Figure 3.3B and C). There was no general correlation (p<0.15)
between the area-averaged mean OSI and the degree of stenosis, and only sporadic
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correlation when sub-classifications were considered (Figure 3.4). Using the general
correlation analysis, no statistically significant relationship was found between OSI and
any of the defined geometric variables. For the OSI piecewise correlation analyses, there
is at least one geometric variable with stronger correlation as compared to degree of
stenosis in each subclassification range. Area-averaged mean RRT exhibits a consistent
negative correlation to the degree of stenosis, with the strongest relation in the least
stenosed vessels (0.67 < S < 0.80) (Figure 3.4).
3.4.3

Regression models
Multiple linear regression models were generated using the defined geometric

variables that correlated with CFD hemodynamic variables (p<0.1), as well as potential
interactive effects among these geometric variables. For each of the hemodynamic
variables, the following general and piecewise regression models were obtained:
TWASS
General:
𝑀𝑒𝑎𝑛 𝑇𝐴𝑊𝑆𝑆 [Pa] =
261.44 − 274.7 × 𝑆 − 488.04 × 𝑚
" / + 564.64 × 𝑆 × 𝑚
"/,

𝑝 < 0.001

Piecewise:
𝑀𝑒𝑎𝑛 𝑇𝐴𝑊𝑆𝑆 [Pa] =
17.94 − 3.47 × 𝑚
" / − 19.30 × 𝑚/ + 20.58 × 𝑚
" / × 𝑚/ 0.67 < 𝑆 < 0.80, 𝑝 = 0.075
".
\ 8.8104 + 17.278 × 𝑚

0.80 ≤ 𝑆 < 0.90, 𝑝 = 0.035

−1754.8 + 1856.9 × 𝑆 + 49.77 × 𝑚
"/

0.90 ≤ 𝑆 < 1.00, 𝑝 = 0.002

OSI
General:

----
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Piecewise:
𝑀𝑒𝑎𝑛 𝑂𝑆𝐼 [−] =
0.009 + 0.017 × 𝐶/
⎧
⎪0.07 − 0.04 × 𝑚
" / − 0.02 × 𝑚/ − 0.01 𝑚/ × 𝑚
"/

0.67 < 𝑆 < 0.80, 𝑝 = 0.066
0.80 ≤ 𝑆 < 0.90, 𝑝 = 0.001

" . − 0.01 × 𝑚
" / − 0.18 𝑆 × 𝑚
" . + 0.01 × 𝑚
". × 𝑚
"/
⎨ −0.24 + 0.28 × 𝑆 + 0.16 × 𝑚
⎪
⎩
0.90 ≤ 𝑆 < 1.00, 𝑝 = 0.010
RRT
General:
𝑀𝑒𝑎𝑛 𝑅𝑅𝑇 [Pa?& ] =
0.355 − 0.1437 × 𝑆 + 0.609 × 𝐶/ − 0.504 × 𝑚
" / + 0.265 × 𝑚. − 0.63 × 𝑆 × 𝐶/
+ 0.493 × 𝑆 × 𝑚
" / − 0.341 × 𝑆 × 𝑚. − 0.068 × 𝐶/ × 𝑚
"/
+ 0.0566 × 𝐶/ × 𝑚. + 0.0184 × 𝑚
" / × 𝑚.

𝑝 < 0.001

Piecewise:
𝑀𝑒𝑎𝑛 𝑅𝑅𝑇 [Pa?& ] =
9.82 − 10.6 × 𝑆 − 10.92 × 𝐶. − 0.44 × 𝑚
" . + 12.41 × 𝐶. × 𝑚
".
⎧
0.67 < 𝑆 < 0.80, 𝑝 = 0.011
⎪
⎪
−3.93 + 4.64 × 𝑆 + 4.67 × 𝐶/ + 1 × 𝑚. − 5.31 × 𝑆 × 𝐶/ − 1.14 × 𝑆 × 𝑚.
⎨
0.80 ≤ 𝑆 < 0.90, 𝑝 < 0.001
⎪
⎪
⎩ 1.11 + 1.20 × 𝑆 + 1.06 × 𝑚. − 1.10 × 𝑆 × 𝑚.
0.90 ≤ 𝑆 < 1.00, 𝑝 = 0.018
The descriptive and predictive capabilities of identified regression models were
evaluated by comparing model- and CFD-derived values of hemodynamic response
variables (Figure 3.5). While no significant general regression model was obtained for OSI,
piecewise regression resulted in significant descriptive and predictive models (Figure
3.5B). Piecewise as opposed to general regression modeling resulted in a substantial
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improvement in both the descriptive and predictive capabilities with respect to TAWSS
and RRT (Figures 3.5A and C).
3.5

DISCUSSION
The present study involves presurgical CTA scans from 50 patients with sufficient

carotid artery stenosis to meet the current NASCET guidelines for the recommendation of
surgical intervention (i.e. carotid endarterectomy). These guidelines, although the current
gold standard for surgical decision making, inherently rely on one geometric parameter
determined at one axial plaque location 127. Several experimental and computational studies
have elucidated the importance of other geometrical attributes of the plaque on flowinduced wall shear stress, flow reversal and stenosis progression 24,107,128. To that end, the
primary goal of this study was to identify a set of novel local geometric variables that can
collectively predict local wall shear stress and related hemodynamic indicators of risk in
highly stenotic carotid arteries. Although risk assessment in CAS is highly multifactorial,
this work focuses on predicting local shear stress levels based on patient-specific geometry.
Regions with complex geometries are susceptible to focal complications arising
from low WSS, exemplified by the prevalence of carotid atheroma in the vicinity of the
carotid bifurcation 129,130. Conversely, moderately elevated WSS (~30 Pa) can promote the
formation of lumen thrombus and severely elevated WSS (over 40 Pa) can cause local
endothelial injury and denudation 131. Several previous studies have examined trends in the
TAWSS in severely stenotic cases; Li et al. reported TAWSS as high as 73 Pa located distal
to the point of maximal stenosis in a patient-specific model 120. A similar observation was
made by Su et al., noting elevated TAWSS (79 Pa) with 90% stenosis, compared to baseline
values that were less than 12 Pa 132. As reported in the literature and observed this study,
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stenosis generally elevates TAWSS but does so in a complex manner that is suggestive of
interactive effects with other geometric characteristics 24,128.
Spatial and temporal fluctuations of the WSS vector are quantified by the mean OSI
and RRT. Higher degrees of stenotic occlusion (>50-60%) are associated with a sharp
increase of OSI and RRT

121

. It was shown previously that in an idealized geometry an

increase in stenosis results in larger downstream vortices, and as a result higher magnitudes
of OSI become more prominent farther from the maximum stenosis 121,128. We observed a
reduction in OSI local to the lesion which our results find to be independent of the local
geometry 133,134. OSI, however, does show a positive association with stenosis as occlusion
progresses and demonstrates correlations with parameters other than stenosis at different
stages of the pathology (i.e. three subcategories of stenotic severity). Furthermore, our
qualitative examinations confirmed an increase of OSI distal and proximal to the lesion
site, areas where flow reversal is predominant 133,135.
For RRT, it was shown that the degree of stenosis has a strong negative association
with the RRT, regardless of what sample population was considered. Strong negative
correlation between the degree of stenosis and the mean RRT in the ROI can be explained
with the increased pressure gradient induced by the pathology that will result in lower
residence time while WSS values are maximal 121,133. An interesting outcome of this study
is that all correlating proximal characteristics showed a positive relation with the RRT, and
almost all distal parameters a negative relation. Among all geometric variables that
demonstrated correlation within sub-classifications, the positive correlation between 𝑚.
and the mean RRT remained consistent and thus is strong candidate variable to predict
RRT directly from CTA images.
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3.5.1

Limitations
While our study incorporated a total of 50 cases and yielded multiple significant

predictors of local hemodynamic variables, identified regression models may not be
relevant to non-severe cases. In these models, vessel walls are assumed rigid; results might
differ in models with deformable vessel walls and when fluid-structure interactions are
accounted for. Furthermore, CFD models were built using patient-specific geometries, but
representative flow field boundary conditions were applied uniformly across all cases. It is
well acknowledged that the application of an inlet flow waveform acquired from a healthy
patient diminishes the direct translational relevance of obtained results; however, uniform
boundary conditions (among cases) were selected to facilitate isolation of geometric
determinants of local wall shear stress. Additionally, all CFD models in this study were
generated under the laminar flow assumption. While previous studies suggest a likely
transition to turbulent flow in the case of highly stenotic carotid arteries, we only
considered laminar flow

109,136–138

. Future iterations of our work will consider new

segmentation methods in which flux-based higher order tensor is utilized for an improved
modeling accuracy at branching points

139

. Finally, our computational models must be

validated in future studies via comparing predictions to results acquired from fourdimensional flow magnetic resonance imaging (MRI) and reference CFD analysis results
140

.

3.6

CONCLUSION
Our study is based on the definition and quantification of a novel set of local

geometric variables which extended beyond the degree of stenosis. Computational results
predict that key geometric variables, in addition to the degree of stenosis, significantly
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modulate local wall shear stress (and related metrics) in the context of severe CAS.
Moreover, piece-wise multiple linear regression modeling suggests that different sets of
geometric variables (which include the degree of stenosis) are determinants of wall shear
stress across case subclassifications based solely on the degree of stenosis. We expect that
different sets of geometric determinants would manifest under lower degrees of stenosis,
which could be identified in CFD-based analyses and potentially influence surgical
decision making in the context of CEA.
3.7
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Table 3.1: Definition of geometric variables with respective formulae.
Geometric variables

Definition

Degree of stenosis; S

= 1 − CHGDCFC ;(G)

Proximal tortuosity; τI

=
between the vessel centerline at the proximal end
ODPMHEQK
of the region of interest and Smax

Distal tortuosity; τO

= ODPMHEQK between the vessel centerline at the distal end of
the region of interest and Smax

CDEDCFC ;(G)

JKELMN

JKELMN

Proximal luminal
concavity; CI

= gRG"

Distal luminal
concavity; CO

= gRG"

R" ;

%&'(/*+,-./

g , where A is a quadratic function of distance

on proximal side; A(x) = ax * + bx + c.
R" ;

%&'(/*+,-./

g , where A is a quadratic function of distance

on distal side; A(x) = ax * + bx + c.
01

Proximal areaaveraged slope; m
"I

0(%&'(/*+,-./
G
∫1 %&'(/*+,-./
;

=
dx , where A is a quadratic
function of distance on proximal side; A(x) = ax * + bx + c.
01

Distal area-averaged
slope; m
"O

=
dx , where A is a quadratic
function of distance on distal side; A(x) = ax * + bx + c.

Stenosis-to-proximalend slope; mI

= g∆T

Distal-end-to-stenosis
slope; mO

= g∆T

0(%&'(/*+,-./
G
∫1 %&'(/*+,-./
;

∆;
%&'(/*+,-./

g, where ∆A is the area change over length on

proximal side of the region of interest.
∆;
%&'(/*+,-./

g, where ∆A is the area change over length on

distal side of the region of interest.
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Figure 3.1: Carotid artery reconstruction and the 2D illustration of stenotic carotid
artery.
(A) Carotid artery reconstruction steps; CTA imaging output shown by a stack of 2D
images of a representative carotid artery segment, extracted boundaries to define the
surface of the arterial lumen, surface model and the linear tetrahedral volumetric mesh. (B)
The maximal stenosis Smax and cross-sectional area A(x) are depicted. XD and XP specific
center-point locations in the distal and proximal directions, respectively.

49

Figure 3.2: Descriptive statistics of CTA-based geometric variables and results
obtained from CFD simulations.
(A) Each bar represents a range of values. The length of each bar denotes the frequency of
each range for each of the geometric variables; Degree of Stenosis; 𝑆, Proximal Tortuosity;
𝜏. , Distal Tortuosity; 𝜏/ , Proximal Luminal Concavity; 𝐶. , Distal Luminal Concavity;
𝐶/ , Proximal Area-Averaged Slope; 𝑚
" . , Distal Area-Averaged Slope; 𝑚
" / , Stenosis-toProximal-end Slope; 𝑚. and Distal-end-to-Stenosis Slope; 𝑚/ . (B) - output variables
calculated from CFD simulations; TAWSS, OSI and RRT.
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Figure 3.3: 3D mapping of CFD results for representative samples from each stenotic
subclassification, and the distribution of hemodynamics vs. the degree of stenosis.
3D mapping of results from CFD simulations for a representative sample of reconstructed
geometries selected from each of the three ranges of stenotic severity (0.67 < S < 0.80, 0.80
≤ S < 0.90 and 0.90 ≤ S < 1.00) and the distribution of hemodynamic variables with respect
to the degree of stenosis for all samples. Stenosis severity ranges from 0.67 < S < 1 and
datapoints are labeled with different colors indicating the severity category (Green: 0.67 <
S < 0.80, Blue: 0.80 ≤ S < 0.90 and Red: 0.90 ≤ S < 1.00). (A) 3D mapping of TAWSS for
three representative cases and distribution of TAWSS with respect to degree of stenosis.
(B) 3D mapping of OSI for three representative cases and distribution of OSI with respect
to degree of stenosis. (C) 3D mapping of RRT for three representative cases and
distribution of RRT with respect to degree of stenosis. (For interpretation of the references
to color in this figure legend, the reader is referred to the Web version of this article.)
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Figure 3.4: Spearman correlation analysis results for ρ demonstrating the strength of
the association between hemodynamic and geometric variables.
(A) Spearman correlation coefficient and statistical significance assessment using the
general approach and including all samples. (B-D) – using the piecewise approach with
0.67 < S < 0.80, 0.80 ≤ S < 0.90 and 0.90 ≤ S < 1.00, respectively. ρ>0 and ρ<0 values are
shaded with shades of red and blue, respectively. darker shades indicate greater magnitudes
of ρ values. (* indicates p-value<0.1 and ** indicates p-value<0.05). (For interpretation of
the references to color in this figure legend, the reader is referred to the Web version of
this article.)
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Figure 3.5: Relationship between hemodynamic variables obtained from CFD results
with respect to the regression models and respective residuals.
(A) Distribution of the TAWSS from CFD and regression models (general and piecewise)
obtained using 45 cases. Filled data points show values predicted by the model that were
not used in development of the model (5 cases). (Right:) Distribution of residuals with
respect to the degree of stenosis for all samples using general regression and piecewise
regression model; filled data points indicate results from the piecewise model. (General
model average residual and standard deviation: 0.86 and 3.10, respectively. Piecewise
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model average residual and standard deviation: 0.28 and 0.90, respectively). (B)
Distribution of the OSI from CFD and piecewise regression model obtained using 45 cases.
Filled data points show values predicted by the model that were not used in development
of the model (5 cases). (Right:) Distribution of residuals with respect to the degree of
stenosis for all samples using piecewise regression model. (Average residual and standard
deviation: 0.35 and 1.18, respectively). (C) Distribution of the RRT from CFD and
regression models (general and piecewise) obtained using 45 cases. Filled data points show
values predicted by the model that were not used in development of the model (5 cases).
(Right:) Distribution of residuals with respect to the degree of stenosis for all samples using
general regression and piecewise regression model; filled data points indicate results from
the piecewise model. (General model average residual and standard deviation: 0.46 and
1.27, respectively. Piecewise model average residual and standard deviation: 0.43 and 1.18,
respectively). For all (A), (B) and (C), datapoints are labeled with different colors (Green,
Blue and Red; from low to high) indicating their associated stenosis severity category, and
dotted lines represent 95% confidence intervals. (For interpretation of the references to
color in this figure legend, the reader is referred to the Web version of this article.)
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CHAPTER 4
INTRINSIC COATING MORPHOLOGY MODULATES ACUTE DRUG
TRANSFER IN DRUG-COATED BALLOON THERAPY3

3

Chang G. H.*, Azar D. A.*, Lyle C., Chitalia V. C., Shazly T., Kolachalama V. B. 2019.
Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon
therapy. Nature Springer - Scientific Reports. 9:6839. *Indicates equal contribution.
DOI: https://doi.org/10.1038/s41598-019-43095-9
Reprinted here with permission of publisher.
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4.1

ABSTRACT
The hallmark of drug-coated balloon (DCB) therapy for the treatment of peripheral

vascular disease is that it allows for reopening of the narrowed lumen and local drug
delivery without the need for a permanent indwelling metal implant such as a stent. Current
DCB designs rely on transferring drugs such as paclitaxel to the arterial vessel using a
variety of biocompatible excipients coated on the balloons. Inherent procedural challenges,
along with limited understanding of the interactions between the coating and the artery,
interactions between the coating and the balloon as well as site-specific differences, have
led to DCB designs with poor drug delivery efficiency. Our study is focused on two
clinically significant DCB excipients, urea and shellac, and uses uniaxial mechanical
testing, scanning electron microscopy (SEM), and biophysical modeling based on classic
Hertz theory to elucidate how coating microstructure governs the transmission of forces at
the coating-artery interface. SEM revealed shellac-based coatings to contain sphericalshaped microstructural elements whereas urea-based coatings contained conical-shaped
microstructural elements. Our model based on Hertz theory showed that the interactions
between these intrinsic coating elements with the arterial wall were fundamentally
different, even when the same external force was applied by the balloon on the arterial
wall. Using two orthogonal cell-based assays, our study also found differential viability
when endothelial cells were exposed to titrated concentrations of urea and shellac, further
highlighting the need to maximize coating transfer efficiency in the context of DCB
therapies. Our results underscore the significance of the excipient in DCB design and
suggest that coating microstructure modulates acute drug transfer during device
deployment.
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4.2

INTRODUCTION
Peripheral arterial disease (PAD) was estimated to affect over 200 million people

around the world in the preceding decade and this number is increasing continuously 141,142.
Endovascular interventions such as percutaneous transluminal angioplasty (PTA) with or
without stenting are among the preferred choices for the treatment of PAD. Recent
randomized controlled clinical trials have demonstrated the superiority of drug-coated
balloon (DCB) therapy when compared to PTA alone, at least in terms of improved patency
and reduced target lesion revascularization 143–147. In all these studies, paclitaxel (PTX) was
the drug of choice but each device differed in terms of the drug dosing, the selection of the
excipient and the overall coating formulation. For example, two DCBs that have recently
obtained regulatory approval within the United States have 3.5 μg/mm2 of PTX with urea
as the excipient (IN.PACT Admiral, Medtronic, Santa Rosa, CA, USA), and 2 μg/mm2 of
PTX with a mixture of polysorbate and sorbitol as the excipient (Lutonix DCB, C. R. Bard,
New Hope, MN, USA), respectively. Additionally, few DCBs that are undergoing clinical
trials as well as the ones in development also use PTX as the drug, (e.g. Stellarex DCB,
Spectranetics, Colorado Springs, CO, USA containing 2 μg/mm2 of PTX with
polyethylene glycol as the excipient). During the endovascular procedure, the belief is that
an optimal coating enables efficient transfer of drug from the balloon to the artery, with
concomitant adherence to the arterial wall. The adhered coating is then expected to serve
as a sustained drug source, leading to a second phase of drug delivery to the arterial wall.
Studies have shown that only a small portion (<8%) of the coating gets transferred during
balloon inflation 148, and almost 90% of the delivered drug is lost within about 24–48 hours
31

. These numbers point to the poor efficiency of drug delivery from balloon catheters.
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Hence, there is a need to better understand the factors influencing delivery efficiency and
what causes these persistent limitations

30,32

. We sought to examine the interactions

between the balloon coating and the arterial wall on multiple scales to better understand
device-dependent arterial pharmacokinetics. We selected PTX as the drug along with urea
and shellac as the excipients for the balloon coating in our experimental study. While a
balloon catheter using urea as an excipient is already in clinical use within the United States
(IN.PACT Admiral, Medtronic) for the treatment of PAD 146,147, a DCB device with shellac
as the excipient (DIOR II, Eurocor) is approved in the European Union for coronary
applications 149. First, we performed a series of bench-top experiments to estimate coatingspecific mechanical behavior that allowed us to characterize the contact between the
balloon coating and the arterial wall. Using these parameters, we developed a biophysical
model to quantify the interfacial mechanics as a function of the intrinsic shape of the
coating microstructure and the force applied by the balloon on the arterial wall. Developed
metrics of interfacial mechanics were then associated with experimental measurements of
arterial drug transfer. To further quantify excipient-based differences among potential
DCBs, we examined cultured human endothelial cell viability when treated with increasing
concentrations of urea and shellac. While the mechanical tests and modeling relate to
essential device function at the time of DCB deployment, the latter studies are relevant to
the notion of increasing coating adherence/retention to serve as a sustained drug source.
Taken together, obtained results underscore the importance of coating composition as a
determinant factor of DCB efficiency and suggest that coating microstructure modulates
the acute drug delivery from these devices.
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4.3

MATERIALS AND METHODS

4.3.1

Preparation of PTX-excipient coated and control films
We developed balloon coatings with PTX and urea (1:1), as well as with PTX and

shellac (1:1), using a micropipetting-coating method. Briefly, urea and shellac, 5–20% w/v,
were dissolved in ethanol-200 at ~200 rpm for 4–6 hours. PTX solution was prepared in
ethanol-200 at 10 mg/mL and added dropwise to the excipient solutions to generate several
(5–20%) w/v mixtures. Each solution was then micropipetted on a sheet of balloon material
(Nylon-12), and was kept at room temperature for 6 hours, which resulted in a coated
surface with 3 μg/mm2 PTX with either excipient. The dried films were cut in 25 × 25 mm
squares and glued to a rigid 3D-printed testing block, creating flat test elements for uniaxial
mechanical testing (Figure 4.1A).
4.3.2

Mechanical characterization of coated balloon in isolation
The compressive mechanical response of coated balloons was measured using a

mechanical testing system (Bose ElectroForce 5270) configured for uniaxial testing. The
test elements were placed between two flat plates, and subjected to a compressive
displacement (0.005 mm/sec) until the force response was 1, 2 or 3 N. Once the target force
was reached, the compression plates were held at the same position for a dwell time of 60
s, following by unloading of the sample at the same displacement rate. Sample force and
displacement data (Figure 4.1B) were continuously recorded at an acquisition rate of 20 s1

using a system-integrated software (Wintest).
To facilitate calculation of the reduced modulus of the coated balloon, the resultant

force-displacement data were fit to a two-term exponential model, defined as:
𝐹 = ∑*!,& 𝑒 U2 V3

(4.1)
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where F is the recorded compressive force, δb is the displacement, and αi are the parameters
for the exponential model (Figure 4.2). The reduced elastic modulus of the coated balloon
then becomes:
&

= √𝐴

W3∗

7V3

(4.2)

7X

where
7V3
7X

4.3.3

= o∑*!,& 𝛼! 𝑒 U2 V3 )q

?&

(4.3)

Mechanical characterization of coated balloon in contact with arterial vessel
During balloon inflation, the coating contacts and directly interacts with the arterial

wall. To facilitate procedural simulation with our coated balloon test elements, we created
analogous flat arterial tissue elements from porcine femoral arteries obtained from a local
abattoir immediately following animal sacrifice (8-12-month-old, 75-125 lbs., male
American Yorkshire pigs). We configured these two elements – the coated balloon and
arterial tissue sample – in series to enable uniaxial compression testing (Figure 4.1A). The
same loading-dwell-unloading protocol as described above was applied to this 2-element
system. Obtained data allowed relation of the overall compliance of this 2-element system
(𝑑𝛿1 /𝑑𝐹) to 𝐸Y∗ (obtained above; Figure 4.1B), and the reduced modulus of the arterial
wall (𝐸8∗ ), as:
&
W5∗

= √𝐴

7V$
7X

−

&
W3∗

(4.4)

where 𝛿1 is the total displacement of the 2-element system, F is the recorded compressive
force, A is the overall contact area between the balloon coating and the arterial wall,
𝐸Y∗ and 𝐸8∗ are the reduced moduli of the balloon and arterial wall, respectively 150,151.
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4.3.4

Scanning electron microscopy
Variable pressure scanning electron microscopy (SEM) (Tescan Vega-3 SBU) was

used to assess the surface microstructure of the coated balloons. Obtained images were
processed to measure the average intrinsic shape of the coatings (MATLAB, MathWorks,
Natick, MA). Each SEM image was first converted to grayscale and then binarized. The
‘regionprops’ feature was used to read all the objects within the binarized image and several
properties including mean perimeter and mean contact angle were estimated that defined
the intrinsic shape of shellac and urea microstructures, respectively (Figure 4.3A and B).
For shellac, we observed a spherical microstructure, whereas for urea, we noticed a micro
needle-like structure with a polygonal cross-section along the length of the needle, thus
representing a conical contact with the arterial surface. Note that the conical contact
assumption was made for cases when the micro needle was lying flat on the arterial surface
or when the tip of the micro needle was in contact with the arterial surface.
4.3.5

Contact mechanics model
We modeled the interactions between the balloon coating and the artery during

balloon angioplasty as an elastic contact problem using the classic Hertz theory. The
surface of the balloon coating has a unique microstructure characterized by its intrinsic
shape and asperity. For PTX-shellac, we assumed that when these spherical microstructures
come in contact with the arterial vessel, they result in an elastic deformation within the
region of the point of contact. This contact region is smaller than the surface area of the
spherical element and is defined using (Figure 4.3C):
𝑎1 = √𝛿𝑅

(4.5)

61

where 𝑎1 is the contact radius, 𝛿 is the indentation depth, and 𝑅 is the radius of the intrinsic
spherical elements

152,153

. The resulting force applied by the spherical element on the

arterial wall then becomes:
'

𝐹1 = [ 𝐸8∗ 𝑅&/* 𝛿 [/*

(4.6)

where 𝐸8∗ is the reduced elastic modulus of the arterial wall. While the force applied results
in the elastic interaction between the spherical coating element and the arterial wall, only
the contact region experiences this force. Thus, the distribution of this force over a smaller
region is quantified by the mean contact pressure 𝑃v = 𝐹1 /(𝜋𝑎1* ). For PTX-shellac, this
becomes:
'
V
𝑃v = [] 𝐸8∗ x^ .

(4.7)

For the case of PTX-urea, the observed needle-like structures were considered as
conical structures with sharp facet angles (Figure 4.3B), where the contact radius is defined
as (Figure 4.3D):
*V

𝑎1 = ]MHE_

(4.8)

where 𝜃 is the angle (assumed as 30°) between the conical shape and the indented surface
152,154

. The total force applied by each conical element then becomes:
*W ∗ V "

5
𝐹1 = ]MHE_

(4.9)

and the mean contact pressure for each element is defined as:
&
𝑃v = * 𝐸8∗ tan𝜃

(4.10)
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4.3.6

Measurement of arterial drug transfer
Stored arterial vessel samples (obtained after mechanical testing) were prepared for

high-performance liquid chromatography (HPLC) to measure the amount of transferred
drug. Each sample was first submerged in methanol and vortexed briefly. The vessel was
then homogenized in methanol for 3 minutes using a probe sonicator and vortexed again
for 10 minutes. The sample was then centrifuged at 1000 rpm for 10 minutes. The
supernatant holding the extracted drug was transferred to a fresh experiment tube. This
sample was diluted in methanol and readied for HPLC testing. The extraction method
above was validated by two control experiments; dissolving known amounts of drug in
methanol and loading drug (paclitaxel) onto vessel samples followed by rapid freezing,
extraction using methanol and dilution prior to HPLC. Then, standard solutions and sample
solutions were analyzed through HPLC.
4.3.7

Cell culture
We performed cell culture experiments to determine if the presence of different

balloon coating materials would affect cell viability. Human umbilical endothelial cells
were cultured as described previously

155

. Cells were maintained at 37°C and 5% CO2.

Early passage cells (less than eight passages) were used for the study.
4.3.8

Flow cytometry
To examine the cytotoxicity of the excipients on live cells, LIVE/DEAD staining

followed by analysis was conducted. Endothelial cells (2×105) were plated in 12 well plates
and were treated for 24 hours with a titrated concentration of the shellac and urea.
Molecular grade ethanol (Pharmco) was used to dissolve shellac (Sigma Aldrich) (10 µM
– 100 mM) and double distilled autoclaved water was used to dissolve urea (Sigma
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Aldrich) (10 µM – 100 mM). Single cell suspensions were analyzed using FACS LSR II
(BD Biosciences). Cells were harvested and viable versus non-viable cells determined by
staining with Zombie UV™ Fixable Viability Kit (Biolegend), as described previously
156,157

. Cells were stained in dark conditions for 30 minutes at room temperature in protein

free phosphate buffered saline. Gating was done on live cells whose intact membranes
prevent dye infiltration while dye positive dead cells were excluded. The positive control
consisted of dead cells, which were induced using Staurosporine 158. Data were analyzed
with Flowjo software (Tree Star).
4.3.9

Cell viability assay
To examine the cytotoxicity of the excipients, viability of the cells was determined

by measuring released ATP using the Cell Titer–Glo Luminescent assay (Promega)
performed using manufacturer’s instructions. Endothelial cells (5×104/100 µL) were plated
on a 96 well plate and treated with various concentrations of 200 proof ethanol (Pharmco)
dissolved shellac (10 µM – 100 mM) and double distilled autoclaved water dissolved urea
(10 µM – 100 mM) for 24 hours. Cell Titer Glo buffer and substrate were equilibrated to
room temperature. The buffer was added to the lyophilized substrate and mixed gently
using vortexing. Equal volume (100 µL) of the homogenous solution was added to the
plated cells. Luminescence was measured with a plate reader. Luminescent signal is
proportional to the amount of ATP. Presence of ATP is directly proportional to the number
of viable cells in culture. Data were analyzed with GraphPad Prism.
4.3.10 Statistical analysis
Descriptive statistics are presented as the mean and standard deviation. Unpaired
Student’s t-test was used to compare experimental groups as appropriate. For some cases,
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significance of the Pearson correlation coefficient was computed using two-tailed
probability, given the correlation value (R2) and the sample size. A p-value less than 0.05
was considered statistically significant.
4.4

RESULTS

4.4.1

Surface morphology of the coatings
SEM imaging allowed us to characterize the distinct morphologic structures of

PTX-urea and PTX-shellac, respectively (Figure 4.3A-B). We performed image processing
on the SEM images to measure the intrinsic shape and the number of microstructures per
unit area of the coating microstructures. The shellac coating consisted of spherical
microstructures with a mean radius of 0.84 μm and a standard deviation of 0.30 μm (Figure
4.3A), and the microstructures distributed densely with 0.18 microstructures per square
micrometer. The urea coating consisted of needle-like crystalline microstructures with a
mean length of 21.6 μm and a standard deviation of 8.5 μm (Figure 4.3B), and the
microstructures distributed more sparsely with 0.003 microstructures per square
micrometer. As these surface morphologic signatures can lead to dissimilar modes of
interaction with the arterial vessel, we hypothesized that these modes can also lead to
differential drug transfer patterns. Additionally, the Hertz theory allowed us to relate SEMobserved intrinsic shapes of the coatings to define the contact regions between the balloon
coating and the vessel wall.
4.4.2

Mechanical properties of the test elements
We leveraged uniaxial compression testing to simulate the coating-artery

interaction during angioplasty. The compression phase of the experiment simulates balloon
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inflation, which was reflected as a gradual increase in tissue displacement with increasing
applied compressive force. The compressive moduli of the test samples were calculated
from the force-displacement (FD) curves during the compression phase. During the 60 s
displacement dwell period, the test constructs underwent a relaxation phase, as indicated
by the gradual reduction in compressive force. During the decompression phase, the
coating is separated from the contact region and the applied force gradually returns to zero,
indicating complete interfacial failure, which could be attributed to adhesive failure of
formed interface and/or fracture of the balloon coating (Figure 4.1B).
The first set of mechanical testing experiments generated FD curves during the
compression phase when shellac- and urea-coated balloons were compressed on flat, rigid
surfaces, respectively (Figure 4.4A-B). These experiments allowed us to estimate the mean
compliance values of both the urea- and shellac-coated balloons at the maximum
compressive force of 1, 2 and 3 N, respectively (Figure 4.4C). Interestingly, there were no
statistically significant differences between the mean compliance values of shellac- and
urea-coated balloons (p=0.36 for 1 N, p=0.41 for 2 N and p=0.62 for 3 N). The second set
of mechanical testing generated FD curves during the compression phase when shellacand urea-coated balloons were compressed on excised femoral arteries opened en face so
that the intraluminal side of the vessel was in contact with the balloon coating (Figure 4.4DE). Mean overall compliance values of the 2-element test constructs were then computed
(Figure 4.4F). Even for this set of experiments, we found no statistically significant
differences between the mean overall compliance values of shellac and urea (p=0.27 for 1
N, p=0.87 for 2 N and p=0.84 for 3 N). Later, for each experiment that generated a unique
FD curve during the compression phase, the compliance of the arterial vessel used for that
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experiment was then computed as the net difference between the overall compliance of the
2-element system and the estimated average compliance of the coated balloon. In this
fashion, we were able to compute arterial sample-specific estimates of compliance, and
these values were used further to quantify the coating-artery interactions. Taken together,
these results imply that within our experimental design space and under the examined mode
of coating-tissue interaction, bulk interfacial mechanics are insensitive to excipient type.
4.4.3

Relating coating-specific interactions with arterial drug transfer
We hypothesized that coating surface microstructure impacts the interactions

between the coating and the arterial wall. We computed the mean contact pressure for each
coating, which is a function of the applied force and the contacting surface area of the
coating (Figure 4.5A). Interestingly, we found statistically significant differences in the
mean contact pressure values between shellac and urea as a function of application force
(p=1.2e-2 for 1 N, p=3.3e-3 for 2 N and p=7.6e-4 for 3 N). We also found that the size of
the contact region was different between urea and shellac, respectively (Figure 4.5B),
regardless of the amount of application force (p=1.0e-4 for 1 N, p=6.0e-4for 2 N and
p=2.2e-3 for 3 N). Importantly, the arterial drug uptake following mechanical testing
correlated with mean contact pressure in a coating-specific fashion (Figure 4.5C; R2 = 0.45,
p=1.3e-2 for urea and R2 = 0.05, p=0.465 for shellac). These results indicate a stronger
correlation of drug uptake with mean contact pressure in the case of urea than for shellac.
Systematic analysis in this fashion can allow us to quantify these relationships to a broad
range of candidate excipients.
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4.4.4

Cytotoxicity of the excipient
While the coating shape-dependent aspects associated with corresponding transfer

of the balloon coating, the task was to determine how these coatings behaved within the
cellular environment. As such, DCBs are placed within the vessel wall, which exposes the
coating directly to the vascular endothelium. To this end, human umbilical endothelial cells
were exposed to titrated concentrations of shellac and urea for 24 hours. The cells were
subjected to LIVE/DEAD and ATP release assays, respectively. Both these assays showed
that low concentrations (10 µM/mL) of shellac and urea did not affect cell viability
compared to vehicle treated cells (Figure 4.6A-B). However, shellac from 10µM to 100µM
resulted in an increase from 8.5% cell death to 30.5% cell death. This change was not found
in similar concentrations of urea. Increasing the concentration of urea from 10µM to
100µM, did not affect cell viability and this trend continued up to a 10,000-fold increase
of urea to 1mM. These data corroborated with the luminescent cell viability assay (Figure
4.6C). Shellac demonstrated a dose-dependent decrease in cell viability. Cells treated with
higher dosages of shellac resulted in decreased ATP levels when compared to cells treated
with the same concentration of urea (Figure 4.6D). Since the presence of ATP is an
indicator of metabolically active cells, this assay strongly suggests that shellac potentially
decreases cell viability at high concentrations. Collectively, both these assays consistently
showed lower viability at an eqimolar concentration of shellac compared to urea.
4.5

DISCUSSION
Catheter-based endovascular therapy involving balloon angioplasty in concert with

local drug delivery is highly appealing as it circumvents the use of permanent indwelling
implants such as stents 27,31,33,34,159–161. Balloon angioplasty alone or angioplasty followed
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by stenting as such have stood the test of time 162, and their strengths as well as limitations
are appreciated by the clinical community. On the other hand, clinical studies focused on
intraluminal delivery of therapeutic compounds from these balloon catheters have
demonstrated great promise but have not yet fully proven to result in a sustained, long-term
benefit 146,163,164. Balloon-vessel contact times are short due to the nature of the procedure
(2–3 min), and moreover, the process of coating transfer from the balloon to the vessel wall
and drug delivery efficiency within this period are not fully understood. Continuation of
this trend can lead to a problem - DCB therapy could remain under-appreciated and
interventional strategies for PAD using currently approved DCBs can lead to sub-optimal
outcomes. It is therefore important to identify factors that promote efficient delivery and
track consequent arterial pharmacokinetics.
Using a series of bench-top experiments and modeling the interaction between the
balloon coating and the arterial wall (Figure 4.1), we computed compliance values of the
arterial wall and mean compliance values of the balloon coating. Using the classic Hertz
theory, we defined shape-specific contact mechanics and the contact force applied on the
arterial wall. Mean contact pressure, which is a function of the contact force and the
intrinsic shape of the coating, was then computed for each of these cases and associated
with corresponding acute transfer of the balloon coating (Figure 4.5E). Also, endothelial
cells exposure to either shellac or urea, induced differential toxic effects that were dosedependent (Figure 4.6). These results underscore the importance of fully characterizing the
nature of the excipients so as to optimize DCB therapy.
The DCB excipient has an important role to play before, during and after balloon
angioplasty. During the pre-procedural or the design phase, a coating technique is used to
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create a thin layer on the surface of the balloon, where the excipient directly plays a role to
support adhesion of the coating to the balloon. During the procedure, as the balloon is
expanded to reopen an occluded arterial vessel, a portion of the balloon-adhered drug
coating detaches from the balloon and gets transferred to the arterial wall. Here, the
excipient acts as the carrier to facilitate rapid drug transfer to the mural surface. The
procedural time is short (~2–3 minutes) but can be logically considered as 2 sub-phases
defined as the compression and decompression of the tissue-balloon interface (Figure
4.1B). During the compression sub-phase, the coating is adhered to the balloon and
concomitantly initiates contact with the mural surface. This mechanical contact initiated
due to the radially outward force generated by balloon expansion leads to adhesion of the
coating to the mural surface. Several properties of the excipient play a role in terms of
dictating the extent of adhesion. During the decompression sub-phase, the radially inward
force generated by balloon deflation generates interfacial failure between the mural surface
and the drug coating and potentially between the balloon and the drug coating. Cohesive
bond failure within the coating itself is also a possibility during the decompression subphase. Once the procedure is completed, the expectation is that the transferred drug coating
continues to adhere to the mural surface, which can lead to a sustained therapeutic response.
In this phase, the excipient acts as an agent to support adhesion and creates a source for
local delivery of drug to the mural surface. In sum, the pre-procedural design
considerations, the procedural aspects involving different modes of bonding failure and
post-procedural phenomenon related to mural adhesion of drug coating can together
determine the success of DCB delivery. As a first step towards fully characterizing the role
of excipients, we focused on quantifying the impact of coating surface morphology and its
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interaction with the mural surface during the procedure on acute transfer of the balloon
coating.
Our study’s main finding is that the unique microstructure of the balloon coating
can directly impact acute transfer of the balloon coating. This is due to the fact that at this
scale, the interaction between a spherical-shaped element and the arterial wall is
fundamentally different from that of a conical-shaped element, even when the same
external force is applied by the balloon on the arterial wall. The classic Hertz theory
allowed us to mathematically decompose this deterministic aspect of contact mechanics
(Figure 4.3C-D) in terms of the mean contact pressure associated with a specific excipient
and application force (Figure 4.5A-B). We found distinct differences in balloon transfer of
paclitaxel as a function of mean contact pressure for urea and shellac (Figure 4.5E).
Our study has some limitations. We used explanted porcine femoral arteries for
mechanical testing and for subsequent measurements of drug transfer. These vessels may
lose some structural integrity immediately after sacrifice, even though we took utmost care
to preserve tissue viability. Our uniaxial mechanical testing protocol is designed to isolate
contact phenomena that likely underlie DCB performance, but does not mimic exact
clinical deployment of these devices. We assumed linear elastic behavior for all
components in our contact mechanical model, although nonlinear effects may become
important at larger strains/strain rates experienced in device deployment. During
mechanical testing, both cohesive and adhesive bond forces play a role during compression
and decompression phases, respectively, and this dynamic may ultimately determine the
amount of drug coating adhered to the vessel wall. We did not attempt to isolate the
individual roles of cohesion and adhesion in the context of our study, as our goal was to
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estimate metrics relevant to balloon-tissue contact and acute drug transfer. This type of
bonding failure (adhesive or cohesive) will dictate the amount of drug coating that is
retained on the mural surface under physiologic conditions (i.e. blood flow), and is thus
significant to drug retention at the application site.
In conclusion, our study connects the application force, which is a procedural factor
that exemplifies balloon angioplasty with the intrinsic shape of the balloon coating
microstructure, which is a design parameter of the device itself. By relating the coatingspecific morphology and its subsequent interactions with the arterial vessel, we have
demonstrated a mechanistic basis by which to evaluate different balloon coatings. While
examination of bulk interfacial mechanics found no coating-specific differences, mean
contact pressure computed by normalizing the application force with the intrinsic shape of
the coating was significantly different between urea and shellac. This means that no two
excipients can be alike in terms of their microscopic mechanical interactions with the
arterial vessel, and when coated on the balloons along with the same drug can still result in
differential arterial pharmacokinetics. Our paradigm can be further used to design coating
formulations that can have maximal balloon transfer of drug, higher arterial uptake and
minimal loss within the systemic circulation, thereby paving way towards efficient
therapeutic approaches using balloon catheters.
4.6
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Figure 4.1: Mechanical testing setup and a typical mechanical testing result.
(A) Mechanical testing setup customized for uniaxial compression testing. Schematic of
the 2-element test system containing the arterial vessel and the drug-coated balloon is also
shown. (B) A typical force-displacement (FD) curve that results from a mechanical test.
Data resulting from the FD curve was used to estimate compliance values of the test
construct.
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Figure 4.2: Force-displacement curves.
(A-C) Average force-displacement curves generated from the compression test. Curvefitting results for the shellac coated balloon with application force of 1N (A), 2N (B) and
3N (C) are shown. (D-F) Average force-displacement curves for the compression test,
followed by curve-fitting results for the urea coated balloon with application force of 1N
(D), 2N (E) and 3N (F) are shown.
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Figure 4.3: Intrinsic shape of the balloon coatings.
SEM imaging revealed a spherical structure for shellac (A), and conical structure for urea
(B). Contact mechanics models were developed based on Hertz theory by considering a
spherical element for shellac (C) and a conical element for urea (D).
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Figure 4.4: Bulk interfacial mechanics are independent of excipient type.
Force-displacement (FD) curves from the mechanical test when shellac (A) and urea (B)
were used as the balloon coating materials, respectively. For (A) and (B), the test element
comprised of the balloon coating compressed on a flat, rigid surface, which allowed us to
estimate the balloon compliance (C) of shellac (indicated by the abbreviation SH) and urea
(indicated by the abbreviation UR), respectively. FD curves from the mechanical test when
shellac (D) and urea (E) were used as the balloon coating materials, respectively, where
the test element comprised of the balloon coating compressed on an excised porcine arterial
vessel. This experiment allowed us to estimate the overall compliance values of the 2element system (F) with shellac and urea, respectively. The dwell time was maintained at
60 s with a maximum application force of 3N.
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Figure 4.5: Excipient microstructure modulates acute transfer of balloon coating.
(A) Mean contact pressure was computed by normalizing the application force with the
intrinsic shape of shellac and urea. (B) Normalized contact radius was different between
shellac and urea as well. Asterisks indicate statistical significance (p<0.05). (C) Net coating
transfer as a function of mean contact pressure for urea and shellac. Data on both axes is
plotted in log-10 scale.
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Figure 4.6: Cytotoxicity of the excipients.
(A) and (B) Cell death with increasing concentrations of shellac and urea. Endothelial cells
(1x106) were treated for 24 hours with increasing concentrations of shellac and urea. Cells
were harvested and stained with Zombie UV™ viability fluorescent dye and analyzed by
flow cytometry. Heat-shocked cells were used as positive control. Ethanol was used as a
vehicle control for shellac and water for urea. Representative Fluorescence Activated Cell
Sorting (FACS) images from two independent experiments is shown. Increase in
concentration of urea did not result in decreased cell viability. (C) Average percentage of
live cells in response to the treatment of shellac and urea done in two independent
experiments is shown. The symbol * indicates p-value that compares live cells between
shellac and urea-treated samples. Also, p = 0.03 for 100 µM, p = 0.005 for 200 µM, p =
0.017 for 500 µM, p = 0.004 for 1000 µM. Standard errors are shown on error bars. (D)
Average of ATP production from two independent experiments is shown. ATP production
indicates the viability of endothelial cells as a function of increasing concentrations of urea
and shellac. The symbol * indicates p-value that compares ATP between shellac and ureatreated cells. Also, p = 0.02 for 100 µM, p = 0.001 for 200 µM, p = 0.001 for 500 µM, p =
0.01 for 1000 µM. Increase in concentration of urea did not compromise ATP production
in endothelial cells. Standard errors are shown on error bars.
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CHAPTER 5
SURFACE MODIFICATION USING ULTRAVIOLET-OZONE
TREATMENT ENHANCES ACUTE DRUG TRANSFER IN DRUGCOATED BALLOON THERAPY4

4
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modification using ultraviolet-ozone treatment enhances acute drug transfer in drugcoated balloon therapy. Submitted to American Chemical Society - Langmuir.
DOI: https://doi.org/10.1021/acs.langmuir.0c00298
Reprinted here with permission of publisher.
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5.1

ABSTRACT
Endovascular deployment of drug-coated balloons (DCB) is an emerging strategy

for revascularization of arterial disease. Randomized clinical trials have demonstrated DCB
effectiveness, but a recent meta-analysis reported increased mortality risk in humans with
use of DCBs containing the common antiproliferative drug paclitaxel. While many factors
could have contributed to adverse outcomes, current DCB designs have poor drug delivery
efficiency, risk of systemic toxicity, and limited potential to retain therapeutic drug
concentrations within the arterial wall following the procedure. Our study focuses on
developing a strategy to enhance acute drug transfer from the balloon to the arterial wall
over the short procedural window (~30-120 secs). We employed ultraviolet-ozone plasma
(UVO) treatment to increase the hydrophilicity of a prototypical balloon material (Nylon12), and subsequently applied a urea-paclitaxel coating previously shown to undergo
favorable adhesive interactions with the arterial wall under simulated ex-vivo deployment.
A series of assays were performed to characterize our experimental DCBs in terms of
UVO-induced

alterations

in

balloon

surface

hydrophobicity,

formed

coating

microstructure, coating stability, and acute drug transfer to the arterial wall. Obtained
results suggest that UVO-based surface modification of angioplasty balloons is a promising
design strategy and highlight the critical role of coating microstructure in determining drug
transfer efficiency in DCB therapy.
5.2

INTRODUCTION
Drug-coated balloon (DCB) therapy is increasingly considered for the treatment of

peripheral arterial disease

145,147,165,166

, as well as for in-stent restenosis (Giacoppo et al.,
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2019) and de novo lesions

167

within the coronary vasculature. An important reason for

adoption of DCB devices is both cost effectiveness and inherent avoidance of a permanent
implant, such as with a metallic-based drug-eluting stent (DES). However, in a recent
summary-level meta-analysis comprising randomized, controlled trials of femoropopliteal
paclitaxel (PTX) coated balloon and stent interventions, 168 identified excess late mortality
in paclitaxel-treated patients 168. Following the publication of this surprising result, the U.S.
Food and Drug Administration (FDA) released a letter to healthcare providers
recommending DCB use in only the highest-risk patients and close post-procedural followup. This has led to a broad clinical pause on the use of DCB devices, as PTX is the drug
used in all the FDA-approved DCBs. While there is no known causal mechanism linking
PTX and mortality, the rapid and extreme FDA response to this recent study underscores
our limited understanding of how DCB devices work and the conditions that can lead to
untoward scenarios. Therefore, there is a clear need for better identification of factors that
govern DCB performance and potentially the introduction of novel formulations that
mitigate long-term adverse events.
Several experimental and computational studies have attempted to identify key
factors driving DCB performance. While some investigations focused on optimizing the
drug-excipient constituents and their ratios on the balloon catheters prior to delivery 169,170,
others have attempted to quantify post-procedural mechanisms related to drug uptake,
retention within the arterial wall 30, and spatiotemporal distribution 171. Moreover, device
manufacturers use several proprietary excipients, touting their ability to effectively deliver
the drug to the vessel wall. Despite such efforts, DCB delivery efficiency remains poor, as
a large majority of drug (~80-90%) gets lost within the systemic circulation
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169,172–174

. In

anticipation of low delivery efficiency, PTX doses on the balloon catheters are an orderof-magnitude higher than typically used with a coronary DES 175. Such high dosing results
in a significant uptake of drug into the vessel wall during the short procedural time (~30–
120 secs), likely saturating all local drug binding sites. Reversible drug binding kinetics
and transport mechanisms then play an important role in determining post-procedural local
drug concentrations; however, the duration over which therapeutic drug levels are
maintained remains unknown. Given the recent setbacks associated with endovascular
PTX delivery and our current knowledge gaps on DCBs, there is a pressing need to
delineate and optimize the key factors governing DCB efficacy 176.
In our previous work 39, we reported that the DCB excipient urea enhances adhesive
interactions between the coating and arterial wall during balloon deployment, and as such
promotes acute PTX transfer. Through biophysical modeling, we further showed that
coating-vessel contact is modulated by the coating microstructure, wherein the needle-like
microstructure of urea-based coatings increases local contact pressures and promotes acute
drug transfer to the arterial wall.
In this study, we extended upon our previous findings by developing a method to
modulate acute drug transfer from urea-based coatings, with the purpose of enhancing PTX
delivery efficiency. We leveraged ultraviolet-ozone plasma (UVO) treatment, a wellknown surface modification technique, to alter the surface properties of the balloon prior
to coating application 177. We characterized UVO-treated balloon surfaces before and after
coating application using dynamic contact angle measurements, scanning electron
microscopy (SEM) and quantitative image analysis. Subsequently, we related the induced
alterations in balloon/coating properties to coating stability and arterial drug transfer in an
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ex-vivo model of DCB deployment. Our findings support UVO-based balloon surface
treatment as a potential strategy to improve drug transfer efficiency, and provide further
evidence linking coating microstructure to acute drug transfer during DCB deployment.
5.3

METHODS
Our study is designed to demonstrate that acute drug transfer from urea-based

DCBs can be enhanced by surface modification of the balloon prior to coating application.
Specifically, we explore UVO treatment as a strategy to modify the surface of Nylon-12.
Our experimental approach entails preparation and characterization of a series of UVOtreated Nylon-12 surfaces, assessment of how these surfaces modulate the microstructure
of a subsequently applied urea-PTX coating, and ex-vivo evaluation of formed coating
stability and drug transfer efficiency when contacting the arterial wall.
5.3.1

Preparation of PTX-urea coatings
Experimental DCBs for PTX delivery were prepared using previously described

techniques. Briefly, coatings containing PTX (LC Laboratories, MA) and urea (Sigma
Aldrich) (w/w 1:1) were prepared via controlled micropipetting of the drug-excipient
solution onto flat Nylon-12 surfaces

178

. The coating solution was formed with agitated

(~200 rpm) dissolution of PTX and urea (15 mg/mL of each constituent) in ethanol (200proof) for 4 hours. Nylon-12 films (0.5 mm thickness) were cut into squares (25 × 25 mm),
sonicated in an ethanol bath at 40°C to remove any potential surface particles, uniformly
coated with urea-PTX solution (120 μL), and stored at room temperature and controlled
humidity (< 5%) for 6 hrs. This process resulted in coated samples with 3 μg/mm2 of each
constituent. In an identical fashion, urea-only and PTX-only coatings were prepared
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(coating density of 3 μg/mm2 for each) for comparative analyses. All samples were stored
in a desiccator at room temperature until use to prevent rehydration.
5.3.2

Surface modification of balloon using UVO treatment
UVO treatment of uncoated balloon films (Nylon-12) was performed in a

commercial UV-ozone surface cleaner (UV/Ozone ProCleaner, Bioforce Nanosciences).
UVO treatment is a photosensitized oxygenation process, which potentiates the addition of
oxygen-based functional groups to the exposed surface (Figure 5.1). During the treatment,
atomic oxygen is continuously produced from ultraviolet-driven ozone-oxygen generation
and dissociation cycle. Nylon-12 films were exposed to UVO treatment for 20, 40 or 60
minutes, immediately after which PTX-urea coatings were applied following the above
protocol.
5.3.3

Balloon hydrophilicity
The dynamic contact angle of an evaporating sessile liquid drop placed on the

balloon surfaces was used to measure hydrophilicity prior to coating application. Image
capture (1.67 frames/sec) spanning the entire evaporation period of a distilled water drop
was performed using a drop shape analyzer (DSA) (Kruss DSA 100 GmbH, Germany), as
previously described
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. Obtained videos were processed with custom build software

developed using MATLAB to determine the dynamic contact angle of a liquid drop. To
account for potential variation in drop volume, dynamic contact angle measurements were
normalized with respect to time under the assumption that all drop sizes were below the
capillary length.
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5.3.4

Coating microstructure
Scanning electron microscopy (SEM) was used to image the surface of urea-PTX

coatings, as well as PTX- and urea-only control coatings. Samples were sputter coated (2.5
kV, 20 mA) with gold-palladium nanoparticles, resulting in a 7.5 Å conductive coating
over the native sample surface. SEM images were acquired at three magnification levels
(100×, 400× and 1400×). A commercial image-analysis package (AMIRA, Thermo Fisher
Scientific, MA, USA) was used to quantify coating surface microstructure. A systematic
edge enhancement protocol was applied to grayscale images followed by conversion to
binary maps. Domains of material that are in aggregate or diffuse forms were separated via
threshold-based separation protocols. Briefly, material domain connections narrower than
5 pixels (~13 μm) were separated. Continuous domains larger than 100 μm2 (domain size
range: 0-50,000 μm2) were categorized as aggregate sites, while those less than 100 μm2
were categorized as diffuse regions. Extracted image parameters include aggregation site
size, distribution, and frequency, as well as diffuse/aggregate material area fraction. To
further quantify aggregate region microstructure, we defined a novel parameter based on
the excluded area from an aggregated site area-equivalent circle superimposed on the
image and positioned at the centroid of aggregate domain.
5.3.5

Coating stability
An in-vitro wash-off assay was used to assess coating stability under pre-

deployment conditions. Coated samples were immersed in Dulbecco’s phosphate buffered
saline (pH 7.2) containing 0.06% (w/v) polyoxyethylene-20 sorbitan monolaurate (Tween
20) and dH2O at 37°C for 30 sec or 3 min. After the submersion period, samples were
retrieved and analyzed for retained PTX content (described below).
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5.3.6

Acute drug transfer to arterial vessel
A uniaxial mechanical testing machine (Bose ElectroForce 5270) was used to

facilitate controlled contact between the arterial vessel samples and experimental DCB
surfaces (Figure 5.2A). DCB peripheral vascular deployment was simulated via a
programmed, three-stage motion of compression-dwell-decompression as previously
described 39 (Figure 5.2B-C). Briefly, fresh porcine (8-12-months old, 75-125 lbs., female
American Yorkshire pigs) femoral arteries were obtained from a local abattoir and used to
form flat, circular (8-mm diameter) test elements. Arterial test elements were mounted onto
test blocks with the endothelium exposed. Analogous test elements/blocks were formed
with experimental DCB surfaces and likewise mounted with the test system. The testing
blocks were placed in controlled no-force contact to initiate testing. The blocks were then
compressed (0.01 mm/sec) until the force reached 8 N, then subjected to a force-controlled
dwell for 30 sec, and finally decompressed (0.01 mm/sec). Both test elements were
isolated, snap-frozen via submersion in liquid nitrogen, and stored at -80°C for further
analysis.
5.3.7

Quantification of PTX
Coated balloon surfaces (obtained after stability test, section 5.3.5) and the arterial

vessel samples (obtained after contact test with coated films, section 5.3.6) were prepared
for liquid chromatography–mass spectrometry (LC-MS) to quantify PTX concentrations.
To extract PTX for LC-MS analysis, each sample was submerged in HPLC-grade methanol
and 0.1% Acidic acid (v/v) and vortexed for 1 min. Acidic acid was added to prevent
transesterification of PTX in methanol. The samples were then sonicated twice for 30
minutes in a water bath sonicator, vortexed for 3 min between two runs, and centrifuged at
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5000 rpm for 10 minutes. The supernatant holding the extracted drug was transferred to a
fresh experiment tube. Each sample was diluted in methanol and prepared for LC-MS
testing. The extraction protocol was validated for each substrate (coated balloon
surfaces/arterial vessel samples) using controls with known amounts of PTX.
5.3.8

Statistical analysis
Standard error and mean were used to present descriptive statistics. Statistical

significance between experimental groups was determined using analysis of variance
(ANOVA) and unpaired t-test. For non-parametric statistical analysis of data with skewed
distribution, a series of Mann-Whitney U tests were used. Pearson’s correlation coefficient
(ρ) was calculated among obtained biophysical variables. A p-value less than 0.05 was
considered statistically significant.
5.4

RESULTS

5.4.1

Coating component morphology
Urea-only coatings exhibited a high degree of aggregation, while PTX-only

coatings exhibited no discernable micro-level architecture with a largely diffuse
appearance (Figure 5.3A-B). The urea-PTX coating formed a distinct, needle-like surface
morphology upon application to untreated Nylon-12 (Figure 5.3C). Preliminary evidence
of coating nucleation sites with urea-PTX motivated the subsequent variant
characterization based on aggregation site frequency, size, and shape.
5.4.2

Balloon surface hydrophobicity
On untreated Nylon-12, the liquid drop had a high mean initial contact angle (85.6

± 6.7°) indicating a natively hydrophobic surface (Figure 5.4A). UVO treatment reduced
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surface hydrophobicity, with an approximately 40% decrease in the mean initial contact
angle following a 20 min treatment (p < 0.001) (Figure 5.4B). Further decreases in the
mean initial contact angle with prolonged UVO treatments (40 and 60 mins) also occurred,
but these changes were comparatively minor and statistically indistinguishable from the
response observed following the 20 min treatment (Figure 5.4C-D). In line with previous
findings on canonical hydrophobic and hydrophilic surfaces

179

, the drop evaporation

dynamics on the untreated Nylon-12 surface was less smooth than observed following
UVO treatment (all treatment times), providing further evidence for a UVO-mediated
decrease in surface hydrophobicity.
5.4.3

Surface morphology of the balloon surfaces
Variably magnified SEM images of urea-PTX coatings on native Nylon-12 further

demonstrate surface heterogeneity and aggregate region formation (Figure 5.5A). UVO
treatment of Nylon-12 notably curtailed PTX-urea coating aggregation, resulting in a
diffuse coating fraction (i.e. not in aggregate form) that became more prevalent with
increased treatment times (Figure 5.5B-D).
Image analysis revealed clear evidence of aggregate region area and site frequency
reductions with UVO treatment but a minimal effect of increased treatment time (Figure
5.6A-B). Qualitative observations of aggregate coating domains (Figure 5.6C) revealed an
increasing divergence from a circular morphology (i) into more outstretched configurations
(ii) with increased treatment time. Image processing of the diffused areas revealed that a
greater number of diffuse crystals with lower length-width ratio were present on the
untreated balloon surface, and these ratios increased with treatment time (Figure 5.5D).
Additional characterization of aggregate domains showed that island sizes were higher on
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the untreated surface and size decreased with treatment time (Figure 5.5E). The aggregate
crystal excluded area (represented by two typical cases in Figure 5.5C) was higher for the
UVO-treated case than the untreated case, indicating that the crystal aggregates formed a
more uniform distribution in the case of the untreated cases, with more dispersion of
aggregate domains with increased treatment time (Figure 5.5F).
5.4.4

Coating stability and acute PTX transfer
UVO treatment did not cause any systematic and significant changes in the amount

of retained PTX after static submersion (Figure 5.7A). However, the amount of acutely
transferred PTX to the vessel wall following simulated DCB deployment increased by
~400% (p<0.05) in the 20-min UVO-treated case as compared to the untreated case (Figure
5.7B). Additional UVO treatment time resulted in no further increase in acute drug transfer.
5.4.5

Response variable correlations
Correlations analyses revealed numerous strong relations among obtained

biophysical response variables (Figure 5.8). Static contact angle and diffuse coating
fraction exhibited a negative correlation, suggesting that increasing surface hydrophilicity
diminished aggregate region formation. A negative correlation was also observed between
contact angle and PTX transfer, linking increasing hydrophilicity to enhanced PTX
delivery efficiency.
5.5

DISCUSSION
Endovascular therapy using DCBs is undergoing additional recent scrutiny. While

several clinical trials have demonstrated DCB efficacy by performing head-to-head
comparison with plain balloon angioplasty

147,165,180
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, and noninferiority with respect to

stent-based counterparts

167,181

, recent findings on late-stage mortality for all PTX-

containing devices have derailed the clinical momentum of DCB therapies 168,182. It is now
incumbent upon the scientific community to provide better characterization of this
therapeutic modality, both in terms of elucidating functional mechanisms and providing
strategies for improved device design. As such, there is extensive focus on identifying
novel excipients to load the drug on the balloon catheter before the angioplasty procedure
180,183

. Note that this portion of research is increasingly attractive for device manufacturers

to claim intellectual property. On the other hand, several studies have also focused on postprocedural mechanisms to better quantify arterial drug transport, tissue binding, and drug
retention

30,184

. However, there is limited focus on the peri-procedural factors that

determine DCB efficacy, and we do not fully understand how to optimize the transfer of a
lipophilic drug such as PTX in combination with an excipient, which is generally
hydrophilic, to the vessel wall within a short procedural time. In this work, we focused on
developing a methodology that allows for enhanced drug transfer from the balloon catheter
to the vessel wall.
Strategies that alter tissue-material interactions upon DCB deployment, including
the presently considered balloon UVO-treatment strategy, can be potentially beneficial
under at least two distinct scenarios. First, enhancing local contact pressures and adhesion
with the vessel wall would promote post-procedural coating retention near/within the
targeted lesion, which potentiates sustained drug delivery via late release from transferred
coating material. Urea-based coatings, by virtue of their microstructural features, promote
such interactions and therefore warrant continued consideration for DCB design 39. Second,
increasing the efficiency of acute PTX delivery with balloon/constituent modification, as
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observed with UVO treatment, enables a reduction in requisite initial drug loading an
insomuch limits the risk of systemic toxicity. UVO-treated, urea-based coatings thus show
potential to enhance DCB efficacy in both scenarios, which motivates their further
consideration in pre-clinical and eventually clinical studies.
Our study suggests key structure-property-function relations that underly DCB
performance, and that these relations can be favorably altered via UVO treatment of the
balloon surface. Specifically, we expect that UVO treatment increases to the presence of
oxygen-containing balloon surface chemical species, which in turn increases the
hydrophilicity of the surface and alters the microstructure of subsequently applied coating
material. The general change in the microstructure can be characterized as a dispersion of
coating material, which from a functional perspective increases the contact area with the
arterial vessel and thus enhances diffusion of drug into the vessel wall during DCB
deployment. Additionally, UVO treatment of the balloon surface, in addition to the
manifest potential for enhancing acute PTX delivery, is also a standard method for
removing surface contaminants and thus could aid in device sterilization

185

. Moreover,

UVO treatment is inexpensive, simple-to-use, and could be easily incorporated into device
preparation.
Our study has the following limitations that should be considered. Although
suggested by previous studies with urea-based coatings, we did not examine if UVO
treatment alters adhesive interactions of the coating and the arterial wall and ultimately
coating transfer. Rather, we focused on developing a strategy to enhance acute drug
transfer, which as mentioned is not the sole determinant of device efficacy. We did not
directly analyze the changes in balloon surface chemistry that occur as a result of UVO
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treatment, but did assess the change in a key surface property (hydrophilicity) – attenuated
total reflectance Fourier transform infrared spectroscopy (FTIR) could be performed in
future studies to address this limitation. Finally, we did not examine if the enhanced acute
PTX transfer impacts long-term drug concentrations in the arterial wall and retention at the
lesion site – subsequent in-vivo studies will provide insight into this critical aspect of DCB
evaluation.
In conclusion, our study examines a translational method of altering the surface
properties of the balloon catheter to enhance acute transfer of PTX to the arterial vessel.
We showed that UVO treatment significantly decreased hydrophobicity of a canonical
balloon material, which promoted more uniform and diffuse formation of a urea-based,
drug-containing coating. Under simulated conditions of balloon angioplasty, there was a
significant increase in acute transfer of the PTX from the balloon to the arterial vessel.
Further studies are required to determine if UVO treatment of the balloon could lead to
long-term clinical benefit in the context of DCBs.
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Figure 5.1: UVO treatment of Nylon-12 films.
Material samples were placed in a commercial UVO surface cleaner. Oxygen-based
functional groups were added to the polymer molecules present on the Nylon-12 films by
exposing them to atomic oxygen in the chamber.

Figure 5.2: Experimental setup design for simulated DCB deployment.
(A) A uniaxial mechanical testing system was utilized to set the interface between arterial
sample and DCB specimens. The system enables automated application of a compressiondwell-decompression protocol, as exemplified by the (B) displacement and (C)
compressive force response curves.
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Figure 5.3: Microstructure of coating constituents.
SEM was used to examine the balloon surface coated with (A) urea only, (B) PTX only,
and (C) PTX-urea. Images were taken at 400x magnification.

Figure 5.4: Contact angle measurement.
Dynamic contact angle of a sessile distilled water drop placed on the balloon surface was
measured. Four scenarios showing contact angle measurements of water drops placed on
(A) untreated Nylon-12 film, as well as UVO-treated Nylon-12 with (B) 20 min, (C) 40
min and (D) 60 min treatment times. Outputs from three independent trials (dotted lines)
along with the average output (solid line), computed from these trials are shown. The
inserts depict the drop profile for the first measured frame.
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Figure 5.5: Coating microstructure changes due to surface modification.
SEM was used to examine the change in microstructure of the balloon surfaces due to UVO
treatment. Four scenarios showing urea-PTX coatings on an (A) untreated balloon surface
as well as UVO-treated Nylon-12 film with (B) 20 min, (C) 40 min, and (D) 60 min
treatment times. Images taken at three different magnifications (100x, 400x and 1400x) are
shown.

Figure 5.6: Morphological analysis of the coatings.
(A) Amount of material in aggregate and diffuse form quantified with binarization and
crystal size-based thresholding with respect to UVO treatment time. Bars shown in black
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denote the total coating material density comprised of diffuse and aggregate material (n=4,
*denotes statistical significance with respect to untreated, p<0.05). (B) Number of
aggregation sites per unit area with respect to UVO treatment time (n=4, *denotes
statistical significance with respect to untreated, p<0.05). (C) Two representative aggregate
crystals are shown for untreated (i) and UVO treated DCB for 60 min (ii) with equivalent
circles placed at the center of gravity. (D) Distribution of length/width parameter for
diffuse crystals with respect to UVO treatment times. (E) Distribution of aggregate crystal
size with respect to UVO treatment times. (F) Aggregate crystal excluded area with respect
to the equivalent circle (shown in panel C for two typical crystals) with respect to UVO
treatment time (n=4, *denotes statistical significance with respect to untreated, p<0.05).
(For interpretation of the references to color in this figure legend, the reader is referred to
the Web version of this article.)

Figure 5.7: Estimation of drug delivery efficiency.
(A) PTX loss from urea-PTX coatings following 30 sec and 3 min static submersion times.
(B) Acute drug transfer to the arterial wall following simulated DCB deployment (n=4,
*denotes statistical significance with respect to untreated, p<0.05).
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Figure 5.8: Correlation among biophysical response variables.
Pearson’s correlation coefficients developed with mean values of response variables
obtained across all urea-PTX coating variants. (* denotes statistical significance between
variables, p<0.05). (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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CHAPTER 6
DISSERTATION SUMMARY AND CONCLUSION
6.1

MAJOR CONTRIBUTIONS TO THE FIELD
The work discussed in this doctoral dissertation is focused on the role of

geometrical features in study of vascular disease severity, advancing clinical decisionmaking process and analysis of a drug delivery device to improve treatment effectiveness
of a minimally-invasive endovascular procedure. These studies, firstly, will provide a
nearly representative framework to understand effects of geometric variables on biophysics
of the simulated phenomenon; Secondly, develop prediction models that are built on
geometric parameters to estimate stress-based disease progression risk which is
translationally applicable to clinical practice and can improve current clinical routines and
outcomes; Finally, find association between intrinsic endovascular device coating
geometry and therapy efficacy with an objective of optimizing drug device design by
utilizing discovered associations between studied variables.
6.2

FUTURE WORKS
Study of geometric features in vascular disease-related conduit abnormalities, such

as topics presented in chapters 2 and 3, motivates considering patient-specific scenarios,
since disease progression and severity may vary with cases considerably. An immediate
next step for these studies is to expand upon treatment technologies. In the case of AAA,
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future work may utilize the previously developed parametric CAD platform to simulate
aneurysmal scenarios and study structural mechanics with addition of an implant, e.g. stent
graft. Given the regional heterogenous geometry and material properties, it is anticipated
that a common stent graft - an endovascular intervention technology – will alter structural
stress levels at high risk areas by application of new boundary conditions at stent anchors.
Therefore, further investigation in this field may result in developing stent graft or stent
anchor designs that are inspired and are specific to a set of aneurysmal scenarios, if not
strictly patient-specific.
Furthermore, the studies regarding the DCB therapy, presented in previous
chapters, investigated current challenges of an existing endovascular technology found
correlation between key design and procedural variables to maximize acute drug transfer.
The reasonably anticipated following study, covered in chapter 5, intended to propose and
evaluate a method to utilize established correlations to produce systematic and repeatable
changes in coating and subsequently, drug transfer. Nevertheless, the proposed
methodology can be further studied to verify added value in comparison to current practices
in the following disciplines: (1) biocompatibility; (2) wash-off during tracking; (3) postdeployment wash-off; (4) drug uptake (vs. acute transfer). We have performed an initial
surface chemistry analysis to understand how UVO-caused changes to surface functional
groups. To that end, X-ray photoelectron spectroscopy (XPS) was used for uncoated DCB
specimens prior to and following UVO. XPS irradiates the sample surface with an x-ray
beam in a vacuum chamber, and can identify chemical elements and bonds between these
elements 186,187. Our preliminary results show that UVO not only generates oxygen-based
species at the surface but also breaks some C-C and C-N bonds (Figure 6.1). Deconvoluted
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peaks and assignment of features for two carbon charging (C 1s) spectra (untreated and 20
min UVO) are shown in Figure 6.1C-D. Increase of balloon surface hydrophilicity
(discussed in chapter 5) as a result of UVO treatment, can be mainly attributed to
oxygenation of Nylon 12 via formation of polar hydroxyl, carbonyl and carboxylic acid
functional groups (Figure 6.1). For treated samples, we noticed a new peak attributed to
formation of carbonates (Figure 6.1D). Since carbonates are active ions, more work in this
field is necessary to evaluate biocompatibility and/or develop reaction protocols to remove
these ions. Additionally, biocompatibility studies should be conducted to further
investigate C-N bond breakdown effects and whether this process will result in NOx
generations. Together, these additional assays can help further developing UVO treatment
as a biocompatible, safe and feasible procedure in commercial production of DCB.
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Figure 6.1: Nylon 12 structure and XPS analysis of UVO surface treatment.
(A) Nylon 12 chemical structure is shown, (B) effect of UVO irradiation time on carbon
bonds is acquired after deconvolution and quantification of C 1s spectra. (C) X-ray
photoelectron spectrum and deconvoluted peaks are shown for - untreated Nylon 12 film.
(D) – UVO-treated Nylon 12 after being treated for 20 minutes. (For interpretation of the
references to color in this figure legend, the reader is referred to the Web version of this
article.)
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